


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:16Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406384" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406384</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jovares</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ovarian Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ovarian Res</journal-id><journal-id journal-id-type="pmc-domain-id">786</journal-id><journal-id journal-id-type="pmc-domain">jovares</journal-id><journal-title-group><journal-title>Journal of Ovarian Research</journal-title></journal-title-group><issn pub-type="epub">1757-2215</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406384</article-id><article-id pub-id-type="pmcid-ver">PMC12406384.1</article-id><article-id pub-id-type="pmcaid">12406384</article-id><article-id pub-id-type="pmcaiid">12406384</article-id><article-id pub-id-type="pmid">40898340</article-id><article-id pub-id-type="doi">10.1186/s13048-025-01790-4</article-id><article-id pub-id-type="publisher-id">1790</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Hyperandrogenism in polycystic ovary syndrome augments Estrogen synthesis through AR-FOXL2&#8211;mediated activation of the aromatase gene in granulosa cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tsai</surname><given-names initials="YR">Yi-Ru</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liao</surname><given-names initials="YN">Yen-Nung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsai</surname><given-names initials="CJ">Cheng-Ju</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="YA">Yu-Ang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hsia</surname><given-names initials="SM">Shih-Min</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lan</surname><given-names initials="KC">Kuo-Chung</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kang</surname><given-names initials="HY">Hong-Yo</given-names></name><address><email>hkang3@mail.cgu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00d80zx46</institution-id><institution-id institution-id-type="GRID">grid.145695.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0922</institution-id><institution>Graduate Institute of Clinical Medical Sciences, College of Medicine, </institution><institution>Chang Gung University, </institution></institution-wrap>Taoyuan, 333 Taiwan </aff><aff id="Aff2"><label>2</label>An-Ten Obstetrics and Gynecology Clinic, Kaohsiung, 802 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00k194y12</institution-id><institution-id institution-id-type="GRID">grid.413804.a</institution-id><institution>Department of Chinese Medicine, College of Medicine, </institution><institution>Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, </institution></institution-wrap>Kaohsiung, 833 Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Graduate Institute of Metabolism and Obesity Sciences, School of Nutrition and Health Sciences, College of Nutrition, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, 110 Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00k194y12</institution-id><institution-id institution-id-type="GRID">grid.413804.a</institution-id><institution>Center for Hormone and Reproductive Medicine Research, Department of Obstetrics and Gynecology, College of Medicine, </institution><institution>Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, </institution></institution-wrap>Kaohsiung, 833 Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00k194y12</institution-id><institution-id institution-id-type="GRID">grid.413804.a</institution-id><institution>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, </institution><institution>Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, </institution></institution-wrap>Kaohsiung, 833 Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mjawt10</institution-id><institution-id institution-id-type="GRID">grid.412036.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0531 9758</institution-id><institution>Department of Biological Science, </institution><institution>National Sun Yat-sen University, </institution></institution-wrap>Kaohsiung, 804 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>18</volume><issue-id pub-id-type="pmc-issue-id">478377</issue-id><elocation-id>200</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13048_2025_Article_1790.pdf"/><abstract id="Abs1" abstract-type="structured"><sec><title>Background</title><p id="Par1">Polycystic ovary syndrome (PCOS) is a complex disorder characterized by various reproductive, metabolic, and endocrine abnormalities. Hyperandrogenism is a key feature of PCOS that significantly impacts ovarian function. However, its effects on granulosa cells (GCs) function for estrogen production in PCOS remains limited.</p></sec><sec><title>Methods</title><p id="Par2">Mouse PCOS-like models were used to investigate the effects of androgen treatments on androgen receptor (AR) downstream gene expression in preantral follicles and primary GCs by qPCR, immunohistochemistry. The expression pattern of AR and FOXL2 was analyzed by single-cell RNA-sequencing analysis, immunohistochemical, and immunofluorescence staining. The AR-FOXL2 interaction was characterized using molecular docking and immunoprecipitation. The functional regulation of the <italic toggle="yes">CYP19A1</italic> promoter by AR-FOXL2 was further analyzed using chromatin immunoprecipitation and dual-luciferase reporter assay. Effects of AR knockdown and inhibitors on estrogen secretion were evaluated in cultured follicles and GCs. Clinical specimens from PCOS patients with hyperandrogenism were analyzed for estrone and estradiol levels in follicular fluid and gene expression in GCs.</p></sec><sec><title>Results</title><p id="Par3">Single-cell RNA sequencing revealed similar expression patterns of AR and FOXL2 across ovarian cell populations. Dihydrotestosterone increased AR protein expression, particularly in preantral follicles, and upregulated both AR and FOXL2 target genes. <italic toggle="yes">CYP19A1</italic> gene that encodes aromatase was significantly elevated in androgens-treated ovaries, follicles, and GCs. Immunofluorescence and co-immunoprecipitation demonstrated that androgen treatment promotes AR-FOXL2 complex formation, enhancing their binding to the <italic toggle="yes">CYP19A1</italic> promoter to directly regulate aromatase transcription in GCs. ChIP-PCR confirmed increased AR binding to three AREs in the promoter II region of <italic toggle="yes">CYP19A1</italic>, with FOXL2 overexpression further enhancing this binding. Elevated estrogen secretion was observed in GCs and cultured follicles, which was attenuated by AR knockdown or inhibition. Clinical samples showed increased estrone, estradiol, and AR, CYP19A1, and FST mRNA expression, with CYP19A1 positively correlating with AR, FOXL2, and estrogen levels.</p></sec><sec><title>Conclusions</title><p id="Par4">Hyperandrogenism in PCOS augments estrogen synthesis in GCs by enhancing AR-FOXL2 interactions, which activate <italic toggle="yes">CYP19A1</italic> gene transcription and thereby increase aromatase expression. This androgen-driven mechanism leads to elevated estrogen levels, offering new insights into the complex pathophysiology of PCOS and strengthening the rationale for targeting the AR-FOXL2-aromatase axis as a therapeutic strategy for ovulation induction in PCOS patients.</p></sec><sec><title>Clinical trial number</title><p id="Par5">Not applicable.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13048-025-01790-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Polycystic ovary syndrome</kwd><kwd>Hyperandrogenism</kwd><kwd>AR</kwd><kwd>FOXL2</kwd><kwd>CYP19A1</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100012553</institution-id><institution>Chang Gung Memorial Hospital</institution></institution-wrap></funding-source><award-id>CMRPG6H0281, CMRPD8H0282-3, CMRPD8K0011-3, CMRPD8L0011-3, CMRPD8N0011-2, CMRPD8Q0011</award-id><award-id>CMRPG6H0281, CMRPD8H0282-3, CMRPD8K0011-3, CMRPD8L0011-3, CMRPD8N0011-2, CMRPD8Q0011</award-id><award-id>CMRPG6H0281, CMRPD8H0282-3, CMRPD8K0011-3, CMRPD8L0011-3, CMRPD8N0011-2, CMRPD8Q0011</award-id><award-id>CMRPG6H0281, CMRPD8H0282-3, CMRPD8K0011-3, CMRPD8L0011-3, CMRPD8N0011-2, CMRPD8Q0011</award-id><award-id>CMRPG6H0281, CMRPD8H0282-3, CMRPD8K0011-3, CMRPD8L0011-3, CMRPD8N0011-2, CMRPD8Q0011</award-id><principal-award-recipient><name name-style="western"><surname>Tsai</surname><given-names>Yi-Ru</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Yen-Nung</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Cheng-Ju</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Yu-Ang</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Hong-Yo</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100020595</institution-id><institution>National Science and Technology Council</institution></institution-wrap></funding-source><award-id>MOST107-2320-B-182-035-MY3 and MOST110-2320-B-182-004-MY3</award-id><principal-award-recipient><name name-style="western"><surname>Kang</surname><given-names>Hong-Yo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Polycystic ovary syndrome (PCOS) is a heterogeneous disease in reproductive-aged women leading to acne, hirsutism, infertility because of biochemical hyperandrogenism, ovulatory dysfunction, and metabolic abnormalities [<xref ref-type="bibr" rid="CR1">1</xref>]. PCOS exhibits diverse clinical features with heterogeneous nature and complexity and lacks a fully understood etiology, resulting in predominantly symptom-based and empirical treatment [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par7">Hyperandrogenism emerges as the predominant endocrine aberrated hallmark of PCOS [<xref ref-type="bibr" rid="CR3">3</xref>]. The polycystic ovary morphology can be manifested under androgen exposure in patients with adrenal hyperplasia [<xref ref-type="bibr" rid="CR4">4</xref>], transgenders [<xref ref-type="bibr" rid="CR5">5</xref>], and animal models [<xref ref-type="bibr" rid="CR6">6</xref>]. Previous studies have provided strong evidence that androgens and their actions through the androgen receptor (AR) are key mediators in PCOS development and pregnancy complications [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Considering that hyperandrogenism is the hallmark of PCOS, several androgen-treated animal models for PCOS have been generated to elucidate the etiology and development of PCOS-associated phenotypes. The most commonly used androgens in these models are testosterone, dehydroepiandrosterone, and dihydrotestosterone (DHT) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The timing of androgen exposure varies widely, starting as early as prenatal exposure. The clinical symptoms of PCOS often start during puberty; hence, treatment of mice before adulthood may more closely resemble human PCOS [<xref ref-type="bibr" rid="CR11">11</xref>]. Indeed, prenatal or prepubertal androgen treatment resembles many characteristics of human PCOS, including anovulation, cystic-like follicles, elevated luteinizing hormone (LH) levels, increased adiposity, and insulin insensitivity [<xref ref-type="bibr" rid="CR9">9</xref>]. Consequently, targeting androgen/AR axis ameliorates the chronic anovulation and menstrual cycle irregularities in PCOS animal models [<xref ref-type="bibr" rid="CR12">12</xref>], highlighting it as a treatment regimen for hyperandrogenic PCOS [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par8">Forkhead box protein L2 (<italic toggle="yes">FOXL2</italic>), a gene encoding a forkhead transcription factor, participates in the regulation of cholesterol and steroid metabolism, apoptosis, reactive oxygen species detoxification, and cell proliferation in the ovary [<xref ref-type="bibr" rid="CR14">14</xref>]. All these recent advances indicate that FOXL2 is a central transcriptional factor required in ovarian development and maintenance [<xref ref-type="bibr" rid="CR15">15</xref>]. Mutant <italic toggle="yes">FOXL2</italic> leads to the pathogenesis of granulosa cell tumor [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In mice, FOXL2 is detected from 12.5 days post-coitum, and its expression continues in the granulosa cells (GCs) and stromal cells of ovarian follicles throughout the female reproductive life [<xref ref-type="bibr" rid="CR18">18</xref>]. The importance of FOXL2 expression extends beyond this initial sex determination stage [<xref ref-type="bibr" rid="CR19">19</xref>]; it is also required in maintaining the ovarian phenotype. The conditional deletion of the <italic toggle="yes">FOXL2</italic> gene in sexually mature female mice leads to the trans-differentiation of GCs into sertoli-like cells and the degeneration of oocytes, suggesting that FOXL2 is required to maintain GC identity in the adult ovary [<xref ref-type="bibr" rid="CR20">20</xref>]. In the postnatal ovary, FOXL2 regulates GCs differentiation and supports follicular growth. In <italic toggle="yes">FOXL2</italic>-/- mice, GCs fail to complete the squamous-to-cuboidal transition, which represents as a gateway to GCs proliferation [<xref ref-type="bibr" rid="CR18">18</xref>]. Without the support of cuboidal GCs, follicular growth is blocked; atresia is also observed in most of the oocytes, with no maturation into secondary follicles [<xref ref-type="bibr" rid="CR19">19</xref>]. In mice, FOXL2 overexpression causes defects in ovary function, such as cell differentiation and steroidogenesis [<xref ref-type="bibr" rid="CR21">21</xref>]. While most studies examined the role of FOXL2 in granulosa cell tumor pathogenesis and folliculogenesis, the roles of FOXL2 in PCOS and the relationship between AR and FOXL2 in the GCs under hyperandrogenic treatments has not yet been investigated.</p><p id="Par9">In the ovary, androgens synthesized from theca cells are converted into estrogens such as estrone (E1) and 17&#946;-estradiol (E2) in GCs by aromatase encoded by the gene cytochrome P450 family 19 subfamily A member 1 (<italic toggle="yes">CYP19A1</italic>) which is known to be regulated by FOXL2 [<xref ref-type="bibr" rid="CR22">22</xref>]. Human aromatase is widely expressed in various tissues, including testis, ovary, placenta, bone, skin, brain, and adipose tissue, as well as benign and malignant tumors such as prostate and breast cancers [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The human <italic toggle="yes">CYP19A1</italic> gene has nine coding exons and numerous alternative noncoding first exons used as tissue-specific promoters that regulate aromatase expression in a tissue- and cell-specific manner [<xref ref-type="bibr" rid="CR25">25</xref>]. Tissue-specific expression of <italic toggle="yes">CYP19A1</italic> gene is achieved through the action of tissue-specific transcription factors and regulatory elements that bind to a specific promoter and enhancer regions of the gene. Promoter PII in the 5&#8242; untranslated region of human <italic toggle="yes">CYP19A1</italic> gene is regulated by follicle-stimulating hormone (FSH) via the protein kinase A/cyclic AMP signaling pathway for proper estrogen production in GCs [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par10">Elevated serum levels of E1 and free testosterone serve as reliable biomarkers with high sensitivity and specificity to distinguish women with PCOS from healthy controls [<xref ref-type="bibr" rid="CR27">27</xref>]. Furthermore, the serum levels of E1 and E2 were both recently found to be increased in women with hyperandrogenemia PCOS compared with those in non-hyperandrogenemia PCOS women [<xref ref-type="bibr" rid="CR28">28</xref>]. These findings are consistent with in PCOS rat models, which also displayed elevated E1 levels [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In AR-knockout (ARKO) mice, DHT did not cause reproductive dysfunction, but testosterone treatment induced irregular cycles and ovulatory disruption [<xref ref-type="bibr" rid="CR7">7</xref>]; thus, direct androgen actions and indirect estrogen actions converted from androgens by aromatase may be both important mediators of PCOS reproductive traits. As <italic toggle="yes">CYP11A1</italic>, <italic toggle="yes">CYP17A1</italic>, and <italic toggle="yes">CYP19A1</italic> polymorphisms are associated with hyperandrogenemia [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] and dysregulation of ovarian steroidogenic enzymes in women with PCOS [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>], this study aimed to investigate whether hyperandrogenism in PCOS may result in AR-FOXL2 axis activation to upregulate ovarian steroidogenic genes and elevate estrogen levels in GCs.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Animals</title><p id="Par11">Three-week-old C57BL/6 female mice were purchased from Biolasco Taiwan Co. Ltd. and maintained at Kaohsiung Chang Gung Memorial Hospital with 12-hour light cycle. All our study procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital.</p></sec><sec id="Sec4"><title>Generation of PCOS-like mouse models</title><p id="Par12">DHT (A8380, Sigma-Aldrich, USA, 15&#160;mg/kg/body weight) was used to induce PCOS-like traits in mice. The dosage of androgen required to induce PCOS was based on previous studies [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Briefly, 4-week female mice were subcutaneously injected once daily with either polyethylene glycol 400 (PEG400, P3265, Sigma-Aldrich, USA) as control group or DHT dissolved in PEG400 to establish the PCOS model for 6 weeks. After complete drug administration, mice (Control group, <italic toggle="yes">n</italic>&#8201;=&#8201;19; DHT group, <italic toggle="yes">n</italic>&#8201;=&#8201;19, 10&#160;mg/kg/body weight) were sacrificed to collect the ovaries and serum.</p></sec><sec id="Sec5"><title>Mouse ovary collection and follicle classification</title><p id="Par13">Dissected ovaries were weighed, dehydrated, and paraffin-embedded at the pathological examination department of Kaohsiung Chang Gung Memorial Hospital. They were serially sectioned at 5&#160;&#956;m. The classification of preantral follicles (oocyte with 2&#8211;5 layers of cuboidal GCs), small antral (oocyte surrounded with &gt;&#8201;5 layers of GCs, and 1 or 2 small areas of follicular fluid), large antral follicles (contained 1 large antral cavity) was based on a previous study [<xref ref-type="bibr" rid="CR38">38</xref>]. For all large antral follicles, the thickness of the granulosa layer and theca layer was measured using Image J software (RRID: SCR_003070).</p></sec><sec id="Sec6"><title>Single-cell RNA-sequencing analysis and data processing</title><p id="Par14">Transcriptomic data of ovaries collected from control mice and PCOS mice performed through Illumina platform was obtained from <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE268919">GSE268919</ext-link>. Mouse genome (GRCm38/mm10) was sourced from UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu">https://genome.ucsc.edu</ext-link>). Cell Ranger (RRID: SCR_023221) and Loupe Browser (RRID: SCR_018555) were utilized in processing and aligning Single-cell RNA-sequencing (scRNA-seq) data. Cell type definition were determined by previous study [<xref ref-type="bibr" rid="CR39">39</xref>] and annotated manually. UMAP was used for visualization of cell type distribution and relationships.</p></sec><sec id="Sec7"><title>Mouse follicle isolation and in vitro culture</title><p id="Par15">Ovaries were collected from 3-week-old C57BL/6 female mice. Large preantral follicles (LPAFs, 110&#8211;170&#160;&#956;m in diameter) with intact GCs layers, round oocyte, and basement membrane were mechanically isolated from dissected ovaries by using acupuncture needles, as previously described [<xref ref-type="bibr" rid="CR40">40</xref>]. We used the &#945;-minimum essential medium (12571063, Gibco, USA) with 10% charcoal/dextran-treated fetal bovine serum (CD-FBS, 12676029, Gibco, USA), recombinant human FSH (10 ng/ml, Gonal-F, Merck, Germany), insulin (10&#160;mg/L), transferrin (5.5&#160;mg/L), sodium selenite (6.7&#160;&#181;g/L, Corning, USA), penicillin (100 units/ml), and streptomycin (100&#160;mg/L; 15240096, Gibco, USA) to cultivate follicles in 96-well plates (1 follicle/well). Follicles were cultured under humid conditions at 37&#160;&#176;C with 5% CO<sub>2</sub>, and half of the medium would change every 2 days. LPAFs (8 follicles/mouse/group) from mice were randomly divided into two groups: VE (medium with ethanol for 48&#160;h) and DHT (medium with 1 &#181;M DHT for 48&#160;h).</p></sec><sec id="Sec8"><title>Isolation of mouse primary GCs</title><p id="Par16">The 3-week-old mouse ovaries were washed with phosphate buffer saline (PBS). Then, minced tissues were digested with collagenase (1&#160;mg/ml; S1746501, Nordmark, Germany) in 0.25% trypsin (15050065, Gibco, USA) and centrifuged at 1000&#160;rpm and 37&#160;&#176;C for 60&#160;min. Furthermore, mouse primary GCs (MPGCs) were separated by filtration using a 40&#160;&#956;m pore size nylon mesh. Filtered MPGCs were allowed to attach on a dish overnight, and then blood cells and tissue debris were washed away with PBS. MPGCs were verified by the IF staining of the FSH receptor (FSHR) antibody (Fig. <xref rid="MOESM1" ref-type="media">S3</xref>).</p></sec><sec id="Sec9"><title>Cell culture, overexpression, and knockdown</title><p id="Par17">Human primary GCs, MPGCs, and KGN (RRID: CVCL_0375, RCB1154, RIKEN BRC Cell bank) were all cultured in DMEM/F12 medium with 10% FBS (10437028, Gibco, USA) in a humidified atmosphere with 5% CO<sub>2</sub> at 37&#160;&#176;C. KGN was transiently overexpressed with FOXL2 (pCS2-flag-FOXL2, 153135, Addgene, Cambridge, MA, USA) via Lipofectamine&#8482; 2000 Transfection Reagent (11668019, Thermofisher, USA) according to the manufacturer&#8217;s instructions. AR in KGN was knocked down by two lentivirus packaging AR-shRNA cloning units (sh-AR-1, TRCN0000350462; sh-AR-2, TRCN0000314730) from Academia Sinica Institutional Animal Care and Utilization Committee (Taipei, Taiwan). The number of viral particles was optimized to infect KGN at a multiplicity of infection of 2&#8211;3 for 3 days. After 3 days of 1&#160;&#181;g/ml puromycin selection, KGN was cultured in fresh medium and prepared for the subsequent experiments.</p></sec><sec id="Sec10"><title>RNA extraction and quantitative RT-PCR</title><p id="Par18">Total RNA was extracted from cells and grinded tissue by using the TRIZOL Reagent. Then, the RNA was reverse-transcribed in 2&#8211;5&#160;&#181;g of the total, using the reverse transcriptase kit (PRA5000, Promega, USA). Next, we incubated the RNA samples at 70&#160;&#176;C for 5&#160;min, immediately chilled in ice water for at least 5&#160;min, and combined with Reverse Transcription Mix. The samples were subsequently incubated at 25&#160;&#176;C for 5&#160;min and at 42&#160;&#176;C for 60&#160;min, and reverse transcriptase was inactivated by heating at 70&#160;&#176;C for 15&#160;min and cooling at 4&#160;&#176;C. The reaction products were stored at 4&#160;&#176;C in the reaction tubes or wells for immediate analysis (up to 24&#160;h) or at &#8722;&#8201;20&#160;&#176;C for long-term storage. We performed RT-PCR in Fast SYBR green master mix kit (4385612, Applied Biosystems, USA). Sequences were analyzed using an ABI 7500 Fast sequence detection system. Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref> lists all the sequences of all primers used in this study. We quantified transcripts of the gene &#946;-actin as the endogenous RNA control and normalized each sample on the basis of its &#946;-actin content. Relative transcription levels were calculated using 2<sup>&#8722;&#916;&#916;CT</sup> methods.</p></sec><sec id="Sec11"><title>ELISAs for E1 and E2 quantification</title><p id="Par19">Seeded 10<sup>4</sup>/cm<sup>2</sup> KGN and 5&#8201;&#215;&#8201;10<sup>4</sup>/cm<sup>2</sup> MPGCs were cultivated in phenol red-free DMEM/F12 medium (21041025, Gibco, USA) with 10% CD-FBS and 1 nM testosterone (86500, Sigma-Aldrich, USA). Furthermore, 10 mouse LPAFs seeded in 96-well plates were cultivated in phenol red-free &#945;-minimum essential medium (41061029, Gibco, USA) with 10% CD-FBS and the necessary supplements as mentioned above. To imitate the hyperandrogenic environment, we treated the cells and follicles with 1 &#181;M androgens (DHT or testosterone) for 48&#160;h. The collected culture media were utilized to measure estrogen levels using the estrone ELISA kit (EU3107, Finetest, China) and 17&#946;-estradiol ELISA kit (ADI-901-008, Enzo, USA).</p></sec><sec id="Sec12"><title>Immunohistochemical, and immunofluorescence staining</title><p id="Par20">Formalin-fixed and paraffin-embedded mouse ovarian sections or seeded GCs underwent immunohistochemica (IHC), and immunofluorescence (IF) staining. The tissue sections were deparaffinized and rehydrated before staining. Regarding the IHC staining, the sections were blocked with 3% hydrogen peroxide blocking reagent for 15&#160;min to deprive the endogenous peroxidase activity, microwaved in 10 mM citrate buffer at pH 6.0 to unmask the epitopes, and then incubated with the primary antibodies overnight in a humidified chamber at 4&#160;&#176;C. After incubation with the secondary IgG antibody, the sections were stained with 3,3&#8242;-diaminobenzidine (DAB, Dako, Glostrup, Denmark) and counterstained with hematoxylin. 5 to 7 ovaries were used in each groups. The intensity of DAB positive staining (H score) in IHC was quantified by IHC profiler (RRID: SCR_023577). H score = (1 &#215; % Low Positive) + (2 &#215; % Positive) + (3 &#215; % High Positive), giving a total score between 0 and 300. As for the IF staining, the sections were incubated overnight with the primary antibody in a humidified chamber at 4&#160;&#176;C after being treated with 10% horse serum to block any nonspecific antibody binding. Moreover, primary antibody binding was visualized using Alexa Fluor<sup>&#174;</sup> 488 Goat Anti-Rabbit IgG (H&#8201;+&#8201;L) (A11034, Invitrogen, USA) and Alexa Fluor<sup>&#174;</sup> 568 Goat Anti-Mouse IgG (H&#8201;+&#8201;L) (A11031, Invitrogen, USA). Finally, the sections were mounted with a mounting medium containing 4&#8217;,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). The images of immunostained FSHR were captured using the Leica DM3000 fluorescence microscope (Leica, Wetzlar, Germany), and the images of double-immunostained AR and FOXL2 were captured using the Olympus FV 1000 confocal microscope system and analyzed with the Olympus Fluoview version 2.1&#160;C software (Olympus Corporation, Tokyo, Japan). Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref> lists all antibodies used in IHC and IF staining.</p></sec><sec id="Sec13"><title>Western blotting</title><p id="Par21">Cells was lysed and sonicated in Radio-Immunoprecipitation Assay buffer, and protein concentration was determined by the Bradford assay. Furthermore, 30&#160;&#181;g of protein was loaded into sodium dodecyl sulfate&#8211;polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes (Amersham Biosciences, USA). The membranes were blocked by 5% nonfat milk/Tris-buffered saline with Tween<sup>&#174;</sup> 20 Detergent for 1&#160;h and probed with the primary antibody at 4&#160;&#176;C overnight. After membrane washing, the secondary antibody was used for incubation for 1&#160;h, and immunodetection was conducted using ECL (PerkinElmer&#8482;, USA). Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref> presents a list of all antibodies used in Western blotting.</p></sec><sec id="Sec14"><title>Molecular docking</title><p id="Par22">The AR-FOXL2 interaction was predicted using HDOCK, a web server [<xref ref-type="bibr" rid="CR41">41</xref>]. Additionally, polar contacts of amino acid residues of the AR and FOXL2 were found, followed by mapping using PyMOL 3.0 (RRID: SCR_000305).</p></sec><sec id="Sec15"><title>Immunoprecipitation</title><p id="Par23">MPGCs lysates were prepared as described above, and protein lysates (500&#160;&#181;g/500 &#181;l) containing 50&#160;&#181;l of magnetic beads (LSKMAGA02, Millipore) were incubated with anti-AR antibody (06-680, Millipore), anti-FOXL2 antibody (ab246511, Abcam, UK), or rabbit IgG (sc-2027, Santa cruz, USA) overnight at 4&#160;&#176;C for immunoprecipitation (IP). Under magnetic bead purification system, beads were washed with PBS, and denatured proteins were collected after boiling. These proteins were then used for Western blotting.</p></sec><sec id="Sec16"><title>Prediction of androgen receptor response element (ARE) in the promoter II region of CYP19A1 gene</title><p id="Par24">We used the Genome Browser data hub UCSC (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link>) to predict the possible AREs in the <italic toggle="yes">CYP19A1</italic> promoter II region, and the JASPAR transcription factor database (<ext-link ext-link-type="uri" xlink:href="http://jaspar.genereg.net/">http://jaspar.genereg.net/</ext-link>) to analyze the presence of AR-binding sites in this region.</p></sec><sec id="Sec17"><title>Chromatin immunoprecipitation</title><p id="Par25">We used an EZ-Magna ChIP assay kit (MAGNA0017, Millipore, USA) to conduct Chromatin immunoprecipitation (ChIP) according to the manufacturer&#8217;s instructions. KGN was cross-linked in 1% formaldehyde and then sonicated. After centrifugation, cell lysates containing immune complexes were incubated with anti-AR (5153&#160;S, Cell Signaling Technology, Boston, MA, USA), anti-RNA polymerase II (05-623B, Millipore, USA), or normal IgG at 4&#160;&#176;C overnight with rotation. We kept 1% of diluted lysates for the DNA input group. After the immune complexes were washed thrice with washing buffer, the DNA fragments were eluted and analyzed using PCR.</p></sec><sec id="Sec18"><title>Luciferase reporter gene assays</title><p id="Par26">We seeded 5&#8201;&#215;&#8201;10<sup>3</sup>/cm<sup>2</sup> KGN cells 18&#160;h before transient transfection with constructs of pGL4-<italic toggle="yes">CYP19A1</italic>-promoter II-589&#160;bp-luciferase. Dual-Luciferase Reporter Assay System (E1910, Promega, USA) was applied to determine the ratio of firefly luciferase activity to Renilla luciferase activity in the samples to represent the biological activity of luciferase reporter constructs.</p></sec><sec id="Sec19"><title>Clinical sample selection</title><p id="Par27">The study was approved by the Ethics Committee of Chang Gung Memorial Hospital and conducted at An-Ten Obstetrics and Gynecology Clinic. Samples were obtained from patients who provided informed consent between September 2023 and December 2023 (IRB approval number: 202301022B0). PCOS diagnosis was based on the 2003 Rotterdam diagnostic criteria, which require two of the following three manifestations: (1) oligo- and/or anovulation, (2) hyperandrogenism, and (3) polycystic ovaries morphology. We selected 13 patients for the PCOS group determined by the Rotterdam diagnostic criteria with hyperandrogenemia. These patients then received the standard in vitro fertilization (IVF) flexible-start antagonist stimulation protocol. For the control group, we selected another 13 women who underwent IVF treatment with regular menstrual cycles, normal sex hormone levels, and normal ovarian morphology. Patients who had adrenal hyperplasia, Cushing&#8217;s syndrome, and thyroid diseases were excluded. The blood and follicular fluid samples were collected from the participants during the oocyte retrieval surgery (approximately 35&#8211;36&#160;h after administering the human chorionic gonadotropin/gonadotropin-releasing hormone agonist). The body mass index (BMI) values, hormonal, biochemical parameters of the control and PCOS groups were documented. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> summarizes patients&#8217; clinical information. The follicular fluid of the largest, first punctured follicle was collected. All the selected follicles were surrounded by the cumulus-oocyte complexes. The ovarian follicles were aspirated independently. Human primary GCs were isolated from the participants&#8217; follicular fluid samples by using histopaque Ficoll 1077 (10771, Merck, Germany). First punctured follicular fluid was used to evaluate E1 and E2 levels via estrone enzyme-linked immunosorbent assay (ELISA) (EU3107, Finetest, China) and 17&#946;-estradiol ELISA (ADI-901-008, Enzo, USA), respectively. Human primary GCs from patients with PCOS were further verified by IF staining with FSHR antibody (Fig. <xref rid="MOESM1" ref-type="media">S3</xref>).</p></sec><sec id="Sec20"><title>Statistical analysis</title><p id="Par28">Experiments were repeated independently at least thrice. Data were presented as mean&#8201;&#177;&#8201;standard error of the mean (SEM) via GraphPad Prism 6 (RRID: SCR_002798). For parametric tests, the statistical significance between two groups was determined by two-tailed Student&#8217;s t test and three or more groups was evaluated by one-way analysis of variance (ANOVA) with Bonferroni&#8217;s test. A <italic toggle="yes">p</italic>-value less than 0.05 was considered statistically significant.</p></sec></sec><sec id="Sec21"><title>Results</title><sec id="Sec22"><title>Comparison of AR, and FOXL2 and their downstream gene expression profiling in PCOS models</title><p id="Par29">To investigate to investigate the expression patterns and downstream signaling pathways of AR and FOXL2 which may play crucial roles in the hyperandrogenic characteristic of PCOS, scRNA-seq dataset was used to establish cell-specific gene expression patterns across ovarian cell populations. The cell population from control and PCOS-like mouse models were further clustered into six subgroups (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A, <xref rid="MOESM1" ref-type="media">S1</xref>). Granulosa cells, thecal cells, stroma cells, perivascular cells, endothelial cells, and immune cells was classified by subpopulation-specific markers followed by the previous study [<xref ref-type="bibr" rid="CR39">39</xref>]. Notably, feature plots demonstrated that both AR and FOXL2 exhibit similar expression patterns across ovarian cells including granulosa cells, thecal cells, stroma cells populations (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B), indicating potential functional interplay between AR and FOXL2 signaling pathways in regulating the follicular development of ovarian physiology and PCOS pathology.</p><p id="Par30">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>AR and FOXL2 downstream genes were activated in both PCOS mouse ovaries and DHT-treated MPGCs. (<bold>A</bold>) Distinct cell type patterns of control and PCOS mouse ovarian populations were classified into granulosa cells, thecal cells, stroma cells, perivascular cells, endothelial cells, and immune cells with different colors by scRNA-seq.&#160;(<bold>B</bold>) Feature plots showed similar expression profiles of AR and FOXL2 within the control and PCOS populations by UMAP visualization. (<bold>C</bold>) AR and (<bold>E</bold>) FOXL2 protein expression patterns in the different follicles of ovary samples isolated from the control and PCOS mice by immunohistochemistry staining (<italic toggle="yes">n</italic>&#8201;=&#8201;10&#8211;29). (<bold>D</bold>) AR and (<bold>F</bold>) FOXL2 protein expression intensity in preantral follicles, small and large antral follicles was quantified by H score. Bars represent 100&#160;&#956;m. (<bold>G</bold>) Relative mRNA expression levels of AR and its downstream genes (FSHR, ANGPT1, and LHCGR), (<bold>H</bold>) FOXL2 and its downstream genes (CYP19A1, FST, and STAR) in ovarian samples from control and PCOS mice (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>I</bold>) Expression profiles of AR and its downstream genes, (<bold>J</bold>) FOXL2 and its downstream genes in MPGCs cultured for 72&#160;h in the absence or presence of DHT (<italic toggle="yes">n</italic>&#8201;=&#8201;3). Data were analyzed by unpaired <italic toggle="yes">t</italic>-test and were expressed as the mean&#8201;&#177;&#8201;SEM *, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Ctrl, control group (ethanol-treated); VE, vehicle group (ethanol-treated)</p></caption><graphic id="d33e716" position="float" orientation="portrait" xlink:href="13048_2025_1790_Fig1_HTML.jpg"/></fig>
</p><p id="Par31">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Co-localization and interaction of FOXL2 and AR in MPGCs and primary GCs from patients with PCOS. (<bold>A</bold>) FOXL2 and AR were labeled with Alexa488 (green) and Alexa568 (red), respectively. DAPI was counterstained for nuclei. Bars represent 10&#160;&#956;m. Pearson&#8217;s coefficient measured the co-localization of AR and FOXL2 in ethanol (VE)- and DHT-treated (<bold>B</bold>) MPGCs and (<bold>C</bold>) primary GCs from patients with PCOS (<italic toggle="yes">n</italic>&#8201;=&#8201;12&#8211;16). Data were expressed as the mean&#8201;&#177;&#8201;SEM; ***, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Unpaired <italic toggle="yes">t</italic>-test was conducted under 3 independent experiments. (<bold>D</bold>) Representative images of the predicted docking model of AR-FOXL2 interaction with the possibility of forming 3 hydrogen bonds (AR-E773, V786, and H790; FOXL2-T76, and R103), and the distance of hydrogen bonds (angstroms). (<bold>E</bold>) Western blotting of the input and immunoprecipitated samples with anti-AR (IP: AR), anti-FOXL2 (IP: FOXL2), and anti-rabbit IgG (IP: rIgG) antibodies showed the co-IP of FOXL2 with AR and co-IP of AR with FOXL2</p></caption><graphic id="d33e752" position="float" orientation="portrait" xlink:href="13048_2025_1790_Fig2_HTML.jpg"/></fig>
</p><p id="Par32">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Androgen induced CYP19A1 promoter activation. Relative expression of CYP19A1 mRNA in KGN (<bold>A</bold>) treated with 1 &#181;M DHT for 6, 12, 24, and 48&#160;h (<italic toggle="yes">n</italic>&#8201;=&#8201;3) and (<bold>B</bold>) treated with 1 &#181;M DHT for 6&#160;h and/or 100 ng/ml follicle-stimulating hormone (FSH) for 48&#160;h only (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>C</bold>) Relative expression of CYP19A1 in KGN with AR knockdown (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>D</bold>) Putative androgen receptor response elements (AREs) were predicted by UCSC and JASPAR and annotated the human aromatase promoter II (589&#160;bp) sequence cloned on pGL4-luciferase vector. Chromatin immunoprecipitation (ChIP)-PCR was performed in KGN by using AR antibody to quantify the binding of AR on <italic toggle="yes">CYP19A1</italic> gene locus. (<bold>E</bold>) The representative PCR analysis for each putative ARE and (<bold>F</bold>) the quantitative results (<italic toggle="yes">n</italic>&#8201;=&#8201;4). ChIP-PCR was also conducted in KGN to test whether AR binding on <italic toggle="yes">CYP19A1</italic> gene locus would be increased by FOXL2 overexpression. (<bold>G</bold>) The result of western blotting showed the overexpression of FOXL2 in KGN; (<bold>H</bold>) The representative PCR analysis for 3 AREs and (<bold>I</bold>) the quantitative results (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>J</bold>) The upper panel showed AR protein expression in KGN treated with 1 &#181;M DHT and/or 100 ng/ml FSH under a serum-free condition for 24&#160;h; the lower panel showed luciferase assay with the same treatment condition for 24&#160;h (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>K</bold>) The upper panel showed AR expression in AR knockdown KGN treated with 1 &#181;M DHT for 24&#160;h; the lower panel showed luciferase assay with the same treatment condition for 24&#160;h (<italic toggle="yes">n</italic>&#8201;=&#8201;3). Data of mRNA expression and ChIP were analyzed by unpaired <italic toggle="yes">t</italic>-test and Data of luciferase assay were analyzed by one-way ANOVA with the mean&#8201;&#177;&#8201;SEM; *, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p></caption><graphic id="d33e839" position="float" orientation="portrait" xlink:href="13048_2025_1790_Fig3_HTML.jpg"/></fig>
</p><p id="Par33">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Androgen excess increased estrogen levels in follicles and GCs. Expression of aromatase in the follicle of hyperandrogenic mice. (<bold>A</bold>) Representative follicles showing aromatase staining results in the ovary isolated from the PCOS mouse model. (<bold>B</bold>) H score was used to quantify aromatase intensity in preantral follicles and both small and large antral follicles (<italic toggle="yes">n</italic>&#8201;=&#8201;18&#8211;25). Bars represent 100&#160;&#956;m. The levels of (<bold>C</bold>) estrone and (<bold>D</bold>) 17&#946;-estradiol (E2) in follicle culture medium (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>E</bold>) The upper panel showed AR protein expression in AR knockdown KGN, the lower panel showed the levels of E2 in AR knockdown KGN culture medium (<italic toggle="yes">n</italic>&#8201;=&#8201;3). (<bold>F</bold>) The upper panel showed AR protein expression in drug-treated KGN, the lower panel showed the levels of E2 in KGN treated with 100 nM letrozole or 100 nM flutamide culture medium for 48&#160;h (<italic toggle="yes">n</italic>&#8201;=&#8201;3). Data were analyzed by unpaired <italic toggle="yes">t</italic>-test with the mean&#8201;&#177;&#8201;SEM; *, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p></caption><graphic id="d33e894" position="float" orientation="portrait" xlink:href="13048_2025_1790_Fig4_HTML.jpg"/></fig>
</p><p id="Par34">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Relative expression of AR, FOXL2, and FOXL2 downstream genes and correlation between CYP19A1 and AR, and FOXL2 and estrogens in human GCs from control patients (<italic toggle="yes">n</italic>&#8201;=&#8201;13) and patients with PCOS (<italic toggle="yes">n</italic>&#8201;=&#8201;13). (<bold>A</bold>) Quantification of the mRNA levels of AR, FOXL2, CYP19A1, FST and STAR. Data were analyzed by unpaired <italic toggle="yes">t</italic>-test with the mean&#8201;&#177;&#8201;SEM; *, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; **, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01. Association of the relative mRNA expression of CYP19A1 in human GCs with that of (<bold>B</bold>) AR, FOXL2, and (<bold>C</bold>) the levels of estrone and 17&#946;-estradiol in human follicular fluids</p></caption><graphic id="d33e930" position="float" orientation="portrait" xlink:href="13048_2025_1790_Fig5_HTML.jpg"/></fig>
</p><p id="Par35">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>A schematic graph highlights the effects of hyperandrogenism and the roles of AR and its interaction with FOXL2 through binding to androgen receptor response element (ARE) and forkhead/insulin response sequences in the promoter regions of <italic toggle="yes">CYP19A1</italic> gene to induce <italic toggle="yes">CYP19A1</italic> gene transcription, thereby increasing aromatase protein expression and estrogen production. The resulting androgen&#8211;estrogen imbalance appears to be a critical factor in PCOS pathogenesis, likely contributing to PCOS&#8217; hallmark features, including increased preantral and antral follicles, irregular estrous cycles, and oligo-anovulation</p></caption><graphic id="d33e947" position="float" orientation="portrait" xlink:href="13048_2025_1790_Fig6_HTML.jpg"/></fig>
</p><p id="Par36">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic characteristics and relative gene expression of recruited women with and without PCOS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Control group</th><th align="left" colspan="1" rowspan="1">PCOS group</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>&#8201;value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (year)</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">33&#8201;&#177;&#8201;5</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">31&#8201;&#177;&#8201;3</td><td char="." align="char" colspan="1" rowspan="1">0.140</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">21.5&#8201;&#177;&#8201;2.0</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">25.9&#8201;&#177;&#8201;5.7</td><td char="." align="char" colspan="1" rowspan="1"><p>0.015</p><p>*</p></td></tr><tr><td align="left" colspan="1" rowspan="1">E1 in follicular fluid (pg/ml)</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">47.87&#8201;&#177;&#8201;19.55</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">78.10&#8201;&#177;&#8201;29.08</td><td char="." align="char" colspan="1" rowspan="1"><p>0.005</p><p>**</p></td></tr><tr><td align="left" colspan="1" rowspan="1">E2 in follicular fluid (&#181;g/ml)</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">24.28&#8201;&#177;&#8201;11.46</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">78.66&#8201;&#177;&#8201;35.55</td><td char="." align="char" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">AMH in serum (ng/ml)</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">2.49&#8201;&#177;&#8201;1.12</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">6.60&#8201;&#177;&#8201;0.85</td><td char="." align="char" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">T in serum (ng/ml)</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">0.50&#8201;&#177;&#8201;0.31</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">0.93&#8201;&#177;&#8201;0.50</td><td char="." align="char" colspan="1" rowspan="1"><p>0.017</p><p>*</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Number of oocytes retrieved</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">10&#8201;&#177;&#8201;5</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">29&#8201;&#177;&#8201;10</td><td char="." align="char" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr></tbody></table></table-wrap>
</p><p id="Par37">To further characterize androgen effects on the underlying AR and FOXL2-mediated downstream-targeted genes in mouse ovaries and MPGCs, we first performed immunohistochemistry staining to evaluate AR and FOXL2 protein expression in different follicle types (preantral, small antral, and large antral) from isolated mouse ovaries. The preantral follicles in the ovaries of PCOS mouse models exhibited higher AR expression than those in control mouse ovaries (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C and <xref rid="Fig1" ref-type="fig">D</xref>). In contrast, the large antral follicles in ovaries from PCOS mouse models showed lower AR expression than those from control mice (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>D). FOXL2 expression was not significantly different between preantral and antral follicles, regardless of the presence of androgen (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>E, <xref rid="Fig1" ref-type="fig">F</xref>). However, clustering analysis of differentially expressed genes showed that FOXL2 downstream genes associated with folliculogenesis, and steroidogenesis were distinctly expressed in the ovaries of PCOS mice compared to those of control mice (Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). By using RT-PCR, we further analyzed the mRNA expression of AR and its downstream genes, including <italic toggle="yes">FSHR</italic>, angiopoietin 1 (<italic toggle="yes">ANGPT1</italic>), and LH/choriogonadotropin receptor (<italic toggle="yes">LHCGR</italic>), which play critical roles in ovarian function [<xref ref-type="bibr" rid="CR42">42</xref>]. The mRNA expression of these genes was significantly upregulated in PCOS ovaries (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>G), follicles (Fig. <xref rid="MOESM1" ref-type="media">S4</xref>A), and DHT-treated MPGCs (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>I). Subsequently, the mRNA expression levels of <italic toggle="yes">FOXL2</italic>, FOXL2-activated genes (<italic toggle="yes">CYP19A1</italic> and <italic toggle="yes">FST</italic>) and repressed gene (<italic toggle="yes">STAR</italic>) were analyzed. Interestingly, the mRNA expression of <italic toggle="yes">CYP19A1</italic> and <italic toggle="yes">FST</italic> was upregulated, while that of STAR was downregulated in PCOS ovaries (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>H) and MPGCs with DHT treatment (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>J). Similarly, <italic toggle="yes">CYP19A1</italic> gene was also upregulated in antral follicles in the presence of DHT treatment (Fig. <xref rid="MOESM1" ref-type="media">S4</xref>B).</p></sec><sec id="Sec23"><title>AR was co-localized and interacted with FOXL2 in GCs</title><p id="Par38">While FOXL2 downstream genes were regulated by DHT, the relationship between AR and FOXL2 in GCs remains unknown. To explore the interaction between FOXL2 and AR, we first used double IF staining with specific antibodies to detect AR and FOXL2 localization in MPGCs and human primary GCs. Both AR and FOXL2 were expressed in the nucleus of MPGCs and human primary GCs. By using Pearson&#8217;s coefficient analysis, DHT treatment significantly increases co-localization of AR and FOXL2 compared to vehicle treatment. (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A-C). In Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D, a molecular docking model was established to predict the physical interaction between AR and FOXL2 proteins and highlight potential interaction sites with hydrogen bonds between specific amino acid residues: AR (E773, V786, and H790) and FOXL2 (T76 and R103). The co-immunoprecipitation analysis further used to confirm the interaction between AR and FOXL2 in MPGCs. When AR is immunoprecipitated (IP: AR), FOXL2 is pulled down, confirming their physical association. Similarly, when FOXL2 is immunoprecipitated (IP: FOXL2), AR is pulled down in the DHT-treated condition compared to vehicle treatment. (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E). This DHT-dependent manner suggests that androgen signaling enhances the interaction between these two proteins, providing a potential molecular mechanism for how hyperandrogenism affects granulosa cell function in PCOS.</p></sec><sec id="Sec24"><title>FOXL2 coordinates with AR to activate CYP19A1 gene transcription and increases Estrogen levels in GCs</title><p id="Par39">Taking into account that CYP19A1 mRNA increased under hyperandrogenism treatment, we hypothesized that AR may bind to the promoter of <italic toggle="yes">CYP19A1</italic> gene to regulate aromatase expression. Thus, we constructed a reporter gene containing <italic toggle="yes">CYP19A1</italic> promoter PII region sequences to measure the AR transcriptional activity. Indeed, CYP19A1 mRNA expression was significantly increased in KGN with DHT treatment for 6&#160;h (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). Considering that FSH regulates CYP19A1 mRNA by activating its promoter II transcriptional activity [<xref ref-type="bibr" rid="CR43">43</xref>], we examined whether DHT-induced CYP19A1 mRNA expression can be enhanced in the presence of FSH. As shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B, the DHT-induced mRNA expression of <italic toggle="yes">CYP19A1</italic> gene was further augmented by FSH treatment. Conversely, the AR knockdown in KGN by AR-shRNA reduced CYP19A1 mRNA expression (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C). To further investigate the underlying mechanism of AR-FOXL2 interaction on regulating the promoter of <italic toggle="yes">CYP19A1</italic> gene under hyperandrogenism, we further analyzed the ChIP-seq data of FOXL2 and AR-binding peaks on human <italic toggle="yes">CYP19A1</italic> gene by using the Genome Browser data hub UCSC and JASPAR. We identified three putative AREs closed to the FOXL2-binding site in the promoter II region of the human <italic toggle="yes">CYP19A1</italic> gene (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>D). Indeed, ChIP-PCR results demonstrated that DHT increased AR binding to three AREs in the promoter II region of the human <italic toggle="yes">CYP19A1</italic> gene (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>E, <xref rid="Fig3" ref-type="fig">F</xref>). To further investigate whether FOXL2 can enhance AR binding to the ARE regions of the promoter of <italic toggle="yes">CYP19A1</italic> gene, we overexpressed FOXL2 in KGN (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>G). Subsequently, ChIP-PCR results demonstrated that FOXL2 increased the binding ability of AR with AREI and ARE II sites in the <italic toggle="yes">CYP19A1</italic> promoter PII region (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>H, <xref rid="Fig3" ref-type="fig">I</xref>). The transcriptional activity of <italic toggle="yes">CYP19A1</italic> gene promoter II was also activated in the presence of DHT and FSH (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>J) but was suppressed by AR-shRNA (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>K) in luciferase assay. Therefore, the AR-FOXL2 interactive complex may bind to the promoter II region of the human <italic toggle="yes">CYP19A1</italic> gene to activate its transcription, and it may increase the mRNA expression of CYP19A1.</p><p id="Par40">Further IHC staining results indicated that DHT, exclusively enhanced aromatase expression in large antral follicles but not in preantral and small antral follicles (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A, <xref rid="Fig4" ref-type="fig">B</xref>). In parallel, we collected an in vitro culture medium from androgen-treated mouse follicles and examined MPGCs and KGN to determine whether excess androgens can enhance the estrogen levels. The concentrations of E1 and E2 were elevated in the culture medium of mouse follicles with or without testosterone and DHT (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C, <xref rid="Fig4" ref-type="fig">D</xref>). Similarly, the E2 level was increased in testosterone- and DHT-treated MPGCs (Fig. <xref rid="MOESM1" ref-type="media">S5</xref>A) and KGN (Fig. <xref rid="MOESM1" ref-type="media">S5</xref>B). Conversely, testosterone-induced E2 level was suppressed by the knockdown of AR, letrozole (an aromatase inhibitor), and flutamide (an androgen antagonist) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>E and <xref rid="Fig4" ref-type="fig">F</xref>).</p></sec><sec id="Sec25"><title>Estrogen production and CYP19A1 gene expression are increased in patients with PCOS</title><p id="Par41">To explore the differences in the hormone imbalance and characterize the roles of AR and FOXL2 in patients with PCOS, we analyzed the PCOS-related hormone levels in follicular fluids and the expression of AR, FOXL2, and FOXL2 downstream genes, including <italic toggle="yes">CYP19A1</italic>, <italic toggle="yes">FST</italic> (follistatin), and <italic toggle="yes">STAR</italic> (steroidogenic acute regulatory protein) in human primary GCs. Compared with the control group, the PCOS group exhibited not only increases in anti-M&#252;llerian hormone (AMH) and testosterone levels in serum but also increases in E1 and E2 levels in follicular fluids (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). In addition, the mRNA expression of AR, CYP19A1, and FST were upregulated in GCs from patients with PCOS (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A). Further regression analysis showed that increased CYP19A1 mRNA levels in the GCs did not only positively correlate with increased FOXL2 and AR mRNA levels (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B) but also positively correlated with elevated E1 and E2 levels in human follicular fluids (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C).</p></sec></sec><sec id="Sec26"><title>Discussion</title><p id="Par42">PCOS is a complex endocrine disorder affecting reproductive-age women. In this study, we aimed to investigate the effects and molecular mechanisms of hyperandrogenism on GCs dysfunction underlying PCOS. Using both PCOS patient samples in vitro cell and in vivo mouse models, we revealed that excess androgens differentially impact the regulation of steroidogenesis and folliculogenesis in the ovary, with one key regulatory pathway involving AR directly interacting with FOXL2. This interaction promotes <italic toggle="yes">CYP19A1</italic> gene transcription, leading to increased aromatase expression and estrogen synthesis in GCs. (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). These findings elucidate a novel mechanism whereby hyperandrogenism augments the GCs-specific regulation of estrogen synthesis via AR-FOXL2&#8211;mediated activation of the aromatase gene in PCOS.</p><p id="Par43">The etiology of PCOS remains unknown, but androgen excess is widely accepted as the basis of this syndrome. Activation of androgen/AR signaling plays a crucial role in PCOS pathogenesis [<xref ref-type="bibr" rid="CR7">7</xref>]. The administration of the AR blocker, flutamide, not only prevents reproductive dysfunction in PCOS mice [<xref ref-type="bibr" rid="CR8">8</xref>], but attenuates accelerated lipid accumulation in PCOS patients [<xref ref-type="bibr" rid="CR44">44</xref>], likely by reducing androgenic signaling. In addition to hyperandrogenism, hormonal imbalances in PCOS including elevated LH, AMH, prolactin, and inhibin levels [<xref ref-type="bibr" rid="CR45">45</xref>]. E2, is considered the most potent estrogen in humans and exerts effects via estrogen receptor 1(ESR1), estrogen receptor 2 (ESR2) and the G-protein-coupled estrogen receptor [<xref ref-type="bibr" rid="CR46">46</xref>]. E2 plays a crucial role in female reproductive function and may contribute to PCOS development, as suggested by polycystic ovarian morphology found in estradiol valerate&#8211;treated rats [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]; however, its clinical utility as a diagnostic marker for PCOS is limited because of variable ovulatory patterns. Instead, increased serum E1 levels converted from increased androstenedione levels by aromatase was consistently observed in PCOS [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, E1 level is significantly correlated with serum LH and androgen levels in women with PCOS [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Consistent with previous findings [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>], our study revealed that both E1 and E2 levels were significantly increased and positively correlated with CYP19A1 mRNA expression in GCs (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C). The CYP19A1 mRNA levels were also correlated with FOXL2 and AR mRNA levels in the human GCs (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B), suggesting a potential regulatory relationship among these genes to coordinate the regulation of steroidogenesis including estrogen production in GCs.</p><p id="Par44">The activation of androgen-AR pathway significantly impacts metabolism in GCs from women with PCOS, disrupting follicle growth and oocyte maturation [<xref ref-type="bibr" rid="CR52">52</xref>]. AR expression has been significantly associated with the number of follicles in the ovaries of patients with PCOS [<xref ref-type="bibr" rid="CR53">53</xref>]. Within follicles, AR is predominantly expressed in the granulosa and theca cells, where it regulates steroidogenesis and follicular development. Our results showed that the AR protein levels were apparently increased in early-stage follicles but significantly declined in large antral follicles (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C and <xref rid="Fig1" ref-type="fig">D</xref>), consistent with previous findings [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Thus, androgens may have differentially regulated the expression of AR in folliculogenesis in vivo. While PCOS features were induced in female mice by prenatal exposure to nonaromatic DHT, heterozygous and homozygous ARKO mice exposed to DHT maintained comparable ovarian morphology, normal estrous cycling, and corpora lutea numbers [<xref ref-type="bibr" rid="CR56">56</xref>]; hence, genomic AR signaling could be an important mediator in the development of these PCOS traits. Several ovulation-related genes in the mouse ovary for FSHR, cyclooxyganase-2, and amphiregulin (the epidermal growth factor-like factor) are regulated by nonaromatizable DHT [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Ovarian (granulosa) cell-specific ARKO mice showed that AR in GCs is essential to regulate the ovarian gene expression by balancing Ezh2-Jmjd3&#8211;mediated H3K27me3 dynamics [<xref ref-type="bibr" rid="CR42">42</xref>]. However, GABA neuron-specific ARKO mice demonstrated that direct androgen/AR signaling in GABA neurons is largely not required for PCOS-like trait development in the androgenized models of PCOS [<xref ref-type="bibr" rid="CR59">59</xref>]. Thus, follicle arrest in PCOS may be mainly characterized in GCs by the differential regulation of key genes involved in follicle growth and function. Indeed, our studies revealed that several AR downstream targets, such as <italic toggle="yes">FSHR</italic>, <italic toggle="yes">ANGPT1</italic>, and <italic toggle="yes">LHCGR</italic> genes, which were previously reported to be significantly elevated in patients with PCOS [<xref ref-type="bibr" rid="CR60">60</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref>], were increased in hyperandrogenic ovaries and MPGCs (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>G, <xref rid="Fig1" ref-type="fig">I</xref>). Furthermore, the mRNA expression of several FOXL2 downstream genes, such as <italic toggle="yes">CYP19A1</italic>, <italic toggle="yes">FST</italic>, and <italic toggle="yes">STAR</italic> was regulated in hyperandrogenic ovaries and MPGCs under DHT treatment (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>H, <xref rid="Fig1" ref-type="fig">J</xref>). Therefore, a complex interplay may exist between androgen/AR signaling and FOXL2 pathways in ovarian cells, particularly affecting genes involved in steroidogenesis (CYP19A1, STAR) and follicular development (FST). Indeed, AR interacted and co-localized with FOXL2 in the nucleus of primary GCs under DHT treatment (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) to bind to the promoter II region of the human <italic toggle="yes">CYP19A1</italic> gene to activate its transcription and increase the mRNA expression of <italic toggle="yes">CYP19A1</italic> gene (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The differential mRNA expression of STAR and AR between mouse and human primary granulosa cells may result from variability in follicular stage at the time of sample collection. The primary granulosa cells in our study were collected from 3-week-old C57BL/6 female mice and treated with androgens. In contrast, the human primary granulosa cells from PCOS patients were collected during oocyte retrieval surgery and may be influenced by individual variability and clinical procedures, such as prior exposure to controlled ovarian stimulation during IVF treatment. In addition, laboratory mice typically have homogeneous genetic backgrounds, whereas human PCOS patients exhibit significant genetic heterogeneity and insulin resistance and metabolic dysfunction, which may indirectly affect granulosa cell gene expression. These factors likely contribute to heterogeneous expression patterns not typically observed in animal models, which represent more uniform and controlled conditions. Although KGN cells are known for their ability to produce steroid hormones, mimicking the behavior of granulosa cells and being widely accepted for investigation of PCOS studies as an in vitro granulosa cell model, it should be noted that KGN is a cell line derived from a human ovarian granulosa cell tumor and may not fully reflect the physiological responses of primary granulosa cells. Thus, our results need to be interpreted with caution, and future validation using human primary granulosa cells is necessary to ensure the reliability of our findings. The variability in follicular stage and prior IVF stimulation in human samples may also influence the AR-FOXL2 target genes expression, underlining the need for standardization in sample collection and analysis.</p><p id="Par45">The human <italic toggle="yes">CYP19A1</italic> gene encoded for aromatase has nine coding exons and multiple alternative noncoding first exons used as tissue-specific promoters that contain a distinct set of regulatory sequences controlled by the combined action of specific transcriptional factors in a tissue- and cell-specific manner [<xref ref-type="bibr" rid="CR25">25</xref>]. The mRNA of <italic toggle="yes">CYP19A1</italic> gene predominantly expressed in GCs and cumulus cells is under the control of PII promoter by several transcriptional regulators, including SF-1, &#946;-catenin, and epigenetic modifications [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Recently, <italic toggle="yes">CYP19A1</italic> gene expression was found to be significantly increased, with increased H3K9ac (activation marker) and decreased H3K9me2 (repression markers), at the PII promoter of <italic toggle="yes">CYP19A1</italic> gene in cumulus cells in PCOS [<xref ref-type="bibr" rid="CR64">64</xref>]. The insight into whether these epigenetic mechanisms are involved in the AR-FOXL2 to cooperatively mediate <italic toggle="yes">CYP19A1</italic> gene transcription in patients with PCOS remains unclear.</p><p id="Par46">The forkhead box (FOX) protein family comprises evolutionarily conserved transcription factors that act as pioneering factors to establish gene expression patterns and control biological processes [<xref ref-type="bibr" rid="CR65">65</xref>]. FOXA1 and FOXA2, members of this family, are known to interact with AR to regulate transcriptional programs in prostate cancer [<xref ref-type="bibr" rid="CR66">66</xref>]. Since we found that AR interacts with FOXL2 to induce CYP19A1 gene transcription in GCs, it would be interesting to determine whether AR signaling collaborates with other FOX proteins to activate CYP19A1 gene transcription and control estrogen production in other tissues (e.g., testis, prostate, adipose tissue, or placenta) where aromatase is widely expressed.</p><p id="Par47">Several FOXL2 downstream genes associated with folliculogenesis and steroidogenesis were distinctly expressed in the ovaries of PCOS mice (Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). For instance, FOXL2 directly modulates functional enhancer region of ESR2 gene in GCs [<xref ref-type="bibr" rid="CR67">67</xref>] and the peaks of FOXL2 ChIP in mouse ovaries were highly enriched in steroid receptor motifs such as ESR1/2 and AR [<xref ref-type="bibr" rid="CR68">68</xref>]. The FSHR gene, which has also been shown to be modulated by FOXL2, plays a crucial role in mediating FSH actions that are enhanced by androgen/AR signaling [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Given this dual regulation, it would be valuable to conduct ChIP-seq analysis to identify downstream genes involved in aberrant PCOS folliculogenesis that might be cooperatively modulated by FOXL2 and androgen/AR signaling. Our findings demonstrate that AR-FOXL2 complex formation is androgen-dependent, suggesting that PCOS patients with different degrees of hyperandrogenism may exhibit varying levels of this protein complex interaction. Therefore, variations in AR sensitivity or FOXL2 expression may result in different magnitudes of CYP19A1 activation, leading to variable estrogen production among patients. This mechanism may partially explain why some PCOS patients have relatively normal estrogen levels while others exhibit significant elevation. Together, variations in the expression levels or functional activity of the overlapping downstream gene network modulated by FOXL2 and AR may contribute to the PCOS heterogeneity and phenotypic diversity.</p><p id="Par48">Furthermore, the AR-FOXL2 signaling status could be assessed through minimally invasive procedures. Granulosa cells obtained during routine follicular aspiration for IVF could be analyzed for AR and FOXL2 expression patterns, providing personalized treatment guidance without additional patient burden. In addition, the development of non-invasive biomarkers based on this pathway could be valuable. Circulating levels of CYP19A1 protein, or specific metabolites reflecting AR-FOXL2 activity, may potentially be measured in blood samples to stratify patients and monitor treatment responses.</p><p id="Par49">Our findings on the AR-FOXL2-aromatase axis in PCOS provide crucial mechanistic insights that strengthen the clinical evidence supporting the use of letrozole for ovulation induction. By demonstrating that hyperandrogenism leads to increased estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in GCs, our study explains why the targeted inhibition of aromatase by letrozole is particularly effective in PCOS patients [<xref ref-type="bibr" rid="CR70">70</xref>]. Mechanistically, aromatase inhibitors block the conversion of androgens to estrogens in ovarian follicles, resulting in decreased circulating estrogens. The reduction in estrogen levels releases the hypothalamo-pituitary axis from estrogen&#8217;s negative feedback, triggering a surge in FSH which promotes normal follicular development with selection of a dominant follicle and atresia of smaller follicles, thereby facilitating follicular growth and ovulation.</p><p id="Par50">This molecular understanding aligns with clinical trial data showing the superiority of letrozole compared to clomiphene citrate in PCOS patients, with higher ovulation rates (82.4% vs. 63.6%), better pregnancy rates (21.6% vs. 9.1%), and lower multiple pregnancy rates (0% vs. 3.2%) [<xref ref-type="bibr" rid="CR71">71</xref>]. Furthermore, by revealing the role of the AR-FOXL2-aromatase axis in granulosa cell estrogen synthesis, our findings not only validate these clinical observations but also provide potential new therapeutic insights for targeting this pathway, establishing a strong scientific foundation for letrozole as a treatment option for ovulation induction in PCOS patients.</p><p id="Par51">During controlled ovarian hyperstimulation cycles, the GCs in PCOS display an exaggerated response to exogenous FSH, thereby augmenting estrogen production. However, our data showed that the MPGCs, the mouse follicles, and the KGN cell line were cultured with androgens stimulation in vitro, they exhibit substantially increased <italic toggle="yes">CYP19A1</italic> gene expression (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>J, S4B and <xref rid="Fig3" ref-type="fig">3</xref>A) and estrogen production (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>D, <xref rid="MOESM1" ref-type="media">S5</xref>). These data suggest that in an isolated environment, androgen stimulation acts directly on the GCs to increase CYP19A1 expression and estrogen production without controlled ovarian hyperstimulation as a potential confounding factor.</p></sec><sec id="Sec27"><title>Conclusion</title><p id="Par52">Due to the heterogeneity of excess androgens and multiple hormonal imbalances in PCOS, the severity and combination of symptoms can vary widely among individuals, leading to different PCOS phenotypes. By combining clinical observations with targeted in vivo and in vitro models, this study revealed androgen impact ovarian function, gene expression, and hormonal production, contributing to the complex pathophysiology of PCOS. Notably, we demonstrate that AR directly interacts with FOXL2 to regulate CYP19A1 gene expression in GCs, thereby modulating increased estrogen synthesis in PCOS. This study may provide valuable insights into the role of chronically elevated estrogens in contributing to the characteristic features of PCOS, including persistent hormonal imbalances, anovulation, metabolic disturbances such as insulin resistance, dyslipidemia, and central adiposity. Moreover, it may also offer a potential explanation for these diverse clinical presentations observed in PCOS, highlighting the complex interplay between ovarian steroidogenesis and systemic metabolic regulation. Nonetheless, it is important to acknowledge that this study is primarily focused on granulosa cells from PCOS patients with hyperandrogenism undergoing IVF treatment, which may not fully represent the complete spectrum of PCOS phenotypes. This introduces several important limitations. Whether similar molecular mechanisms operate in non-IVF populations or in PCOS variants with distinct metabolic features remains unclear. PCOS patients with significant insulin resistance may have altered granulosa cell function due to hyperinsulinemia&#8217;s effects on steroidogenesis, which could modify AR-FOXL2 interactions independently of androgen levels. Our study&#8217;s focus on predominantly reproductive aspects may not capture the full complexity of PCOS pathophysiology in metabolically distinct phenotypes. These considerations underscore the need for caution when generalizing our results to the entire PCOS population. Future investigation of AR-FOXL2-mediated signaling across a more diverse range of clinical phenotypes, including non-IVF and metabolically heterogeneous PCOS patients, is warranted to strengthen clinical relevance. Given that PCOS is a multifactorial condition involving insulin resistance, inflammation, and neuroendocrine dysregulation, our findings represent only one component of this complex disease. Further studies are needed to elucidate the AR-FOXL2 interaction and its downstream transcriptional effects.</p></sec><sec id="Sec28" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM2_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM3_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM4_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM5_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 5</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM6_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 6</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM7_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 7</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM8" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM8_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 8</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM9" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM9_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 9</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM10" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM10_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 10</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM11" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM11_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 11</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM12" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM12_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 12</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM13" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM13_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 13</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM14" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM14_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 14</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM15" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM15_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 15</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM16" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM16_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 16</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM17" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM17_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 17</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM18" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM18_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 18</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM19" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM19_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 19</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM20" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM20_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 20</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM21" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM21_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 21</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM22" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM22_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 22</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM23" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM23_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 23</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM24" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM24_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 24</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM25" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM25_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 25</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM26" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM26_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 26</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM27" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM27_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 27</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM28" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM28_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 28</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM29" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM29_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 29</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM30" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM30_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 30</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM31" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM31_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 31</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM32" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM32_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 32</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM33" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM33_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 33</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM34" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM34_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 34</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM35" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM35_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 35</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM36" position="float" orientation="portrait"><media xlink:href="13048_2025_1790_MOESM36_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 36</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We sincerely thank the patients for their participation and everyone who contributed to this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Yi-Ru Tsai, Cheng-Ju Tsai, and Hong-Yo Kang made substantial contributions to the conceptualization, investigation and validation of the work. Yi-Ru Tsai, Yen-Nung Laio, Cheng-Ju Tsai, Yu-Ang Lee, Shih-Min Hsia, Kuo-Chung Lan and Hong-Yo Kang made contributions to the resources acquisition and analysis of data. Yi-Ru Tsai, Cheng-Ju Tsai and Hong-Yo Kang were contributors in writing the manuscript, and Hong-Yo Kang substantively revised it. Hong-Yo Kang made substantial contributions to the supervision, project administration, funding acquisition. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by research grants from Chang Gung Memorial Hospital (CMRPG6H0281, CMRPD8H0282-3, CMRPD8K0011-3, CMRPD8L0011-3, CMRPD8N0011-2, CMRPD8Q0011) and the National Science and Technology Council of the Republic of China, Taiwan (Contract No. MOST107-2320-B-182-035-MY3, MOST110-2320-B-182-004-MY3 and MOST113-2320-B-182-027-MY3) for financially supporting this research.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par53">Ethical approval of the experiments involved in this study has been acquired from the Ethics Committee of Chang Gung Memorial Hospital (No. CMRPD8L0011-3). The use of samples from human in this study was obtained from the Institutional Review Board of Chang Gung Memorial Hospital (IRB approval number: 202301022B0) All experiments on the animals were designed according to the Guide for the Care and Use of Laboratory Animals (No. 2021061801). All animal investigations were conducted at Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital.</p></notes><notes id="FPar1"><title>Consent for publication</title><p id="Par54">All authors confirm the consent for publication.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>PCOS</term><def><p id="Par56">Polycystic ovary syndrome</p></def></def-item><def-item><term>AR</term><def><p id="Par57">Androgen receptor</p></def></def-item><def-item><term>FOXL2</term><def><p id="Par58">Forkhead box protein L2</p></def></def-item><def-item><term>DHT</term><def><p id="Par59">Dihydrotestosterone</p></def></def-item><def-item><term>LH</term><def><p id="Par60">Luteinizing hormone</p></def></def-item><def-item><term>GCs</term><def><p id="Par61">Granulosa cells</p></def></def-item><def-item><term>MPGCs</term><def><p id="Par62">Mouse primary granulosa cells</p></def></def-item><def-item><term>E1</term><def><p id="Par63">Estrone</p></def></def-item><def-item><term>E2</term><def><p id="Par64">17&#946;-Estradiol</p></def></def-item><def-item><term>CYP19A1</term><def><p id="Par65">Cytochrome P450 family 19 subfamily A member 1</p></def></def-item><def-item><term>FSH</term><def><p id="Par66">Follicle-stimulating hormone</p></def></def-item><def-item><term>ARKO</term><def><p id="Par67">AR-knockout</p></def></def-item><def-item><term>IVF</term><def><p id="Par68">In vitro fertilization</p></def></def-item><def-item><term>ELISA</term><def><p id="Par69">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>IHC</term><def><p id="Par70">Immunohistochemical</p></def></def-item><def-item><term>IF</term><def><p id="Par71">Immunofluorescence</p></def></def-item><def-item><term>scRNA-seq</term><def><p id="Par72">Single-cell RNA sequencing</p></def></def-item><def-item><term>LPAFs</term><def><p id="Par73">Large preantral follicles</p></def></def-item><def-item><term>IP</term><def><p id="Par74">immunoprecipitation</p></def></def-item><def-item><term>ChIP</term><def><p id="Par75">Chromatin immunoprecipitation</p></def></def-item><def-item><term>FSHR</term><def><p id="Par76">FSH receptor</p></def></def-item><def-item><term>VE</term><def><p id="Par77">Vehicle</p></def></def-item><def-item><term>ANGPT1</term><def><p id="Par78">Angiopoietin 1</p></def></def-item><def-item><term>LHCGR</term><def><p id="Par79">LH/choriogonadotropin receptor</p></def></def-item><def-item><term>FST</term><def><p id="Par80">Follistatin</p></def></def-item><def-item><term>STAR</term><def><p id="Par81">Steroidogenic acute regulatory protein</p></def></def-item><def-item><term>ESR</term><def><p id="Par82">estrogen receptor</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Amiri M, Hatoum S, Buyalos RP, Sheidaei A, Azziz R. The influence of study quality, age, and geographic factors on Pcos Prevalence - A systematic review and Meta-Analysis. J Clin Endocrinol Metab 2025;110:2082&#8211;2103.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgae917</pub-id><pub-id pub-id-type="pmid">39758024</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><collab>ACOG Practice Bulletin No</collab></person-group><article-title>194: polycystic ovary syndrome: correction</article-title><source>Obstet Gynecol</source><year>2020</year><volume>136</volume><fpage>638</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000004069</pub-id><pub-id pub-id-type="pmid">32826589</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">ACOG Practice Bulletin No. 194: polycystic ovary syndrome: correction. Obstet Gynecol. 2020;136:638.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000004069</pub-id><pub-id pub-id-type="pmid">32826589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H</given-names></name></person-group><article-title>Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia</article-title><source>Int Immunopharmacol</source><year>2023</year><volume>125</volume><fpage>111141</fpage><pub-id pub-id-type="pmid">37918087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2023.111141</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Xiang Y, Wang H, Ding H, Xu T, Liu X, Huang Z, Wu H, Ge H. Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia. Int Immunopharmacol. 2023;125:111141.<pub-id pub-id-type="pmid">37918087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2023.111141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucis</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Hobkirk</surname><given-names>R</given-names></name><name name-style="western"><surname>Hollenberg</surname><given-names>CH</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>SA</given-names></name><name name-style="western"><surname>Blahey</surname><given-names>P</given-names></name></person-group><article-title>Polycystic ovaries associated with congenital adrenal hyperplasia</article-title><source>Can Med Assoc J</source><year>1966</year><volume>94</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">5901591</pub-id><pub-id pub-id-type="pmcid">PMC1935165</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lucis OJ, Hobkirk R, Hollenberg CH, MacDonald SA, Blahey P. Polycystic ovaries associated with congenital adrenal hyperplasia. Can Med Assoc J. 1966;94:1&#8211;7.<pub-id pub-id-type="pmid">5901591</pub-id><pub-id pub-id-type="pmcid">PMC1935165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pache</surname><given-names>TD</given-names></name><name name-style="western"><surname>Fauser</surname><given-names>BC</given-names></name></person-group><article-title>Polycystic ovaries in female-to-male transsexuals</article-title><source>Clin Endocrinol (Oxf)</source><year>1993</year><volume>39</volume><fpage>702</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8123169</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Pache TD, Fauser BC. Polycystic ovaries in female-to-male transsexuals. Clin Endocrinol (Oxf). 1993;39:702&#8211;3.<pub-id pub-id-type="pmid">8123169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bertoldo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Handelsman</surname><given-names>DJ</given-names></name></person-group><article-title>Evidence from animal models on the pathogenesis of PCOS</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2018</year><volume>32</volume><fpage>271</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">29779581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beem.2018.03.008</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Walters KA, Bertoldo MJ, Handelsman DJ. Evidence from animal models on the pathogenesis of PCOS. Best Pract Res Clin Endocrinol Metab. 2018;32:271&#8211;81.<pub-id pub-id-type="pmid">29779581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beem.2018.03.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aflatounian</surname><given-names>A</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>MC</given-names></name><name name-style="western"><surname>Rodriguez Paris</surname><given-names>V</given-names></name><name name-style="western"><surname>Bertoldo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Desai</surname><given-names>R</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ledger</surname><given-names>WL</given-names></name><name name-style="western"><surname>Handelsman</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Walters</surname><given-names>KA</given-names></name></person-group><article-title>Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model</article-title><source>J Endocrinol</source><year>2020</year><volume>245</volume><fpage>381</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">32229702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JOE-19-0530</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Aflatounian A, Edwards MC, Rodriguez Paris V, Bertoldo MJ, Desai R, Gilchrist RB, Ledger WL, Handelsman DJ, Walters KA. Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model. J Endocrinol. 2020;245:381&#8211;95.<pub-id pub-id-type="pmid">32229702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JOE-19-0530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Derisoud</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>A</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>G</given-names></name><name name-style="western"><surname>Lindgren</surname><given-names>E</given-names></name><name name-style="western"><surname>Pui</surname><given-names>HP</given-names></name><name name-style="western"><surname>Risal</surname><given-names>S</given-names></name><name name-style="western"><surname>Pei</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dissecting the impact of maternal androgen exposure on developmental programming through targeting the androgen receptor</article-title><source>Adv Sci (Weinh)</source><year>2024</year><volume>11</volume><fpage>e2309429</fpage><pub-id pub-id-type="pmid">39075722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202309429</pub-id><pub-id pub-id-type="pmcid">PMC11423211</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lu H, Jiang H, Li C, Derisoud E, Zhao A, Eriksson G, Lindgren E, Pui HP, Risal S, Pei Y, et al. Dissecting the impact of maternal androgen exposure on developmental programming through targeting the androgen receptor. Adv Sci (Weinh). 2024;11:e2309429.<pub-id pub-id-type="pmid">39075722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202309429</pub-id><pub-id pub-id-type="pmcid">PMC11423211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Houten</surname><given-names>EL</given-names></name><name name-style="western"><surname>Visser</surname><given-names>JA</given-names></name></person-group><article-title>Mouse models to study polycystic ovary syndrome: a possible link between metabolism and ovarian function?</article-title><source>Reprod Biol</source><year>2014</year><volume>14</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">24607253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.repbio.2013.09.007</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">van Houten EL, Visser JA. Mouse models to study polycystic ovary syndrome: a possible link between metabolism and ovarian function? Reprod Biol. 2014;14:32&#8211;43.<pub-id pub-id-type="pmid">24607253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.repbio.2013.09.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Chou</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SU</given-names></name><name name-style="western"><surname>Yang</surname><given-names>WS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YS</given-names></name><name name-style="western"><surname>Ho</surname><given-names>HN</given-names></name></person-group><article-title>The effect of androgens on ovarian follicle maturation: dihydrotestosterone suppress FSH-stimulated granulosa cell proliferation by upregulating PPARgamma-dependent PTEN expression</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>18319</fpage><pub-id pub-id-type="pmid">26674985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep18319</pub-id><pub-id pub-id-type="pmcid">PMC4682139</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chen MJ, Chou CH, Chen SU, Yang WS, Yang YS, Ho HN. The effect of androgens on ovarian follicle maturation: dihydrotestosterone suppress FSH-stimulated granulosa cell proliferation by upregulating PPARgamma-dependent PTEN expression. Sci Rep. 2015;5:18319.<pub-id pub-id-type="pmid">26674985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep18319</pub-id><pub-id pub-id-type="pmcid">PMC4682139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franks</surname><given-names>S</given-names></name></person-group><article-title>Adult polycystic ovary syndrome begins in childhood</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2002</year><volume>16</volume><fpage>263</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12064892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/beem.2002.0203</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab. 2002;16:263&#8211;72.<pub-id pub-id-type="pmid">12064892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/beem.2002.0203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>GE</given-names></name><name name-style="western"><surname>Malik</surname><given-names>S</given-names></name><name name-style="western"><surname>Mellon</surname><given-names>PL</given-names></name></person-group><article-title>Antiandrogen treatment ameliorates reproductive and metabolic phenotypes in the Letrozole-Induced mouse model of PCOS</article-title><source>Endocrinology</source><year>2018</year><volume>159</volume><fpage>1734</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">29471436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2017-03218</pub-id><pub-id pub-id-type="pmcid">PMC6097580</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ryan GE, Malik S, Mellon PL. Antiandrogen treatment ameliorates reproductive and metabolic phenotypes in the Letrozole-Induced mouse model of PCOS. Endocrinology. 2018;159:1734&#8211;47.<pub-id pub-id-type="pmid">29471436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2017-03218</pub-id><pub-id pub-id-type="pmcid">PMC6097580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paradisi</surname><given-names>R</given-names></name><name name-style="western"><surname>Fabbri</surname><given-names>R</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>C</given-names></name><name name-style="western"><surname>Venturoli</surname><given-names>S</given-names></name></person-group><article-title>Ovulatory effects of Flutamide in the polycystic ovary syndrome</article-title><source>Gynecol Endocrinol</source><year>2013</year><volume>29</volume><fpage>391</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23327685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09513590.2012.754876</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Paradisi R, Fabbri R, Battaglia C, Venturoli S. Ovulatory effects of Flutamide in the polycystic ovary syndrome. Gynecol Endocrinol. 2013;29:391&#8211;5.<pub-id pub-id-type="pmid">23327685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09513590.2012.754876</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mubeen</surname><given-names>A</given-names></name><name name-style="western"><surname>Parra-Herran</surname><given-names>C</given-names></name></person-group><article-title>FOXL2: a gene central to ovarian function</article-title><source>J Clin Pathol</source><year>2023</year><volume>76</volume><fpage>798</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">37798106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jcp-2023-208827</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mubeen A, Parra-Herran C. FOXL2: a gene central to ovarian function. J Clin Pathol. 2023;76:798&#8211;801.<pub-id pub-id-type="pmid">37798106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jcp-2023-208827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caburet</surname><given-names>S</given-names></name><name name-style="western"><surname>Georges</surname><given-names>A</given-names></name><name name-style="western"><surname>L&#8217;Hote</surname><given-names>D</given-names></name><name name-style="western"><surname>Todeschini</surname><given-names>AL</given-names></name><name name-style="western"><surname>Benayoun</surname><given-names>BA</given-names></name><name name-style="western"><surname>Veitia</surname><given-names>RA</given-names></name></person-group><article-title>The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology</article-title><source>Mol Cell Endocrinol</source><year>2012</year><volume>356</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">21763750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2011.06.019</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Caburet S, Georges A, L&#8217;Hote D, Todeschini AL, Benayoun BA, Veitia RA. The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology. Mol Cell Endocrinol. 2012;356:55&#8211;64.<pub-id pub-id-type="pmid">21763750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2011.06.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>SP</given-names></name><name name-style="western"><surname>Kobel</surname><given-names>M</given-names></name><name name-style="western"><surname>Senz</surname><given-names>J</given-names></name><name name-style="western"><surname>Morin</surname><given-names>RD</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>BA</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>KC</given-names></name><name name-style="western"><surname>Leung</surname><given-names>G</given-names></name><name name-style="western"><surname>Zayed</surname><given-names>A</given-names></name><name name-style="western"><surname>Mehl</surname><given-names>E</given-names></name><name name-style="western"><surname>Kalloger</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Mutation of FOXL2 in granulosa-cell tumors of the ovary</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>2719</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">19516027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0902542</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719&#8211;29.<pub-id pub-id-type="pmid">19516027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0902542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamieson</surname><given-names>S</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>PJ</given-names></name></person-group><article-title>Molecular pathogenesis of granulosa cell tumors of the ovary</article-title><source>Endocr Rev</source><year>2012</year><volume>33</volume><fpage>109</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22240241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2011-0014</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012;33:109&#8211;44.<pub-id pub-id-type="pmid">22240241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2011-0014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>D</given-names></name><name name-style="western"><surname>Ovitt</surname><given-names>CE</given-names></name><name name-style="western"><surname>Anlag</surname><given-names>K</given-names></name><name name-style="western"><surname>Fehsenfeld</surname><given-names>S</given-names></name><name name-style="western"><surname>Gredsted</surname><given-names>L</given-names></name><name name-style="western"><surname>Treier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Treier</surname><given-names>M</given-names></name></person-group><article-title>The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance</article-title><source>Development</source><year>2004</year><volume>131</volume><fpage>933</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">14736745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.00969</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, Treier M. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development. 2004;131:933&#8211;42.<pub-id pub-id-type="pmid">14736745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.00969</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>DTH</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Chu</surname><given-names>S</given-names></name></person-group><article-title>Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors</article-title><source>Int J Biochem Cell Biol</source><year>2016</year><volume>72</volume><fpage>51</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">26791928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2016.01.003</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Leung DTH, Fuller PJ, Chu S. Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors. Int J Biochem Cell Biol. 2016;72:51&#8211;4.<pub-id pub-id-type="pmid">26791928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2016.01.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhlenhaut</surname><given-names>NH</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>S</given-names></name><name name-style="western"><surname>Anlag</surname><given-names>K</given-names></name><name name-style="western"><surname>Eisenberger</surname><given-names>T</given-names></name><name name-style="western"><surname>Sekido</surname><given-names>R</given-names></name><name name-style="western"><surname>Kress</surname><given-names>J</given-names></name><name name-style="western"><surname>Treier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Klugmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Klasen</surname><given-names>C</given-names></name><name name-style="western"><surname>Holter</surname><given-names>NI</given-names></name><etal/></person-group><article-title>Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>1130</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20005806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2009.11.021</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, Kress J, Treier AC, Klugmann C, Klasen C, Holter NI, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 2009;139:1130&#8211;42.<pub-id pub-id-type="pmid">20005806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2009.11.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicol</surname><given-names>B</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>K</given-names></name><name name-style="western"><surname>Yao</surname><given-names>HH</given-names></name></person-group><article-title>Aberrant and constitutive expression of FOXL2 impairs ovarian development and functions in mice</article-title><source>Biol Reprod</source><year>2020</year><volume>103</volume><fpage>966</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">32945847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/biolre/ioaa146</pub-id><pub-id pub-id-type="pmcid">PMC7609876</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Nicol B, Rodriguez K, Yao HH. Aberrant and constitutive expression of FOXL2 impairs ovarian development and functions in mice. Biol Reprod. 2020;103:966&#8211;77.<pub-id pub-id-type="pmid">32945847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/biolre/ioaa146</pub-id><pub-id pub-id-type="pmcid">PMC7609876</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Baddela VS, Michaelis M, Tao X, Koczan D, Vanselow J. ERK1/2-SOX9/FOXL2 axis regulates ovarian steroidogenesis and favors the follicular-luteal transition. Life Sci Alliance 2023;6:e202302100.<pub-id pub-id-type="doi" assigning-authority="pmc">10.26508/lsa.202302100</pub-id><pub-id pub-id-type="pmcid">PMC10397509</pub-id><pub-id pub-id-type="pmid">37532283</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name></person-group><article-title>Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review</article-title><source>J Steroid Biochem Mol Biol</source><year>2017</year><volume>168</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">28109841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2017.01.009</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Patel S. Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review. J Steroid Biochem Mol Biol. 2017;168:19&#8211;25.<pub-id pub-id-type="pmid">28109841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2017.01.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Middlemas DS, Ousterhout J. Female Hormone Regulation. <italic toggle="yes">Brody&#8217;s Human Pharmacology-E-Book: Brody&#8217;s Human Pharmacology-E-Book</italic> 2024:446.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Clyne</surname><given-names>C</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>G</given-names></name><name name-style="western"><surname>Boon</surname><given-names>WC</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>K</given-names></name><name name-style="western"><surname>Britt</surname><given-names>K</given-names></name><name name-style="western"><surname>Speed</surname><given-names>C</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M</given-names></name></person-group><article-title>Aromatase&#8211;a brief overview</article-title><source>Annu Rev Physiol</source><year>2002</year><volume>64</volume><fpage>93</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">11826265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.physiol.64.081601.142703</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. Aromatase&#8211;a brief overview. Annu Rev Physiol. 2002;64:93&#8211;127.<pub-id pub-id-type="pmid">11826265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.physiol.64.081601.142703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manna</surname><given-names>PR</given-names></name><name name-style="western"><surname>Molehin</surname><given-names>D</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>AU</given-names></name></person-group><article-title>Dysregulation of aromatase in breast, endometrial, and ovarian cancers: an overview of therapeutic strategies</article-title><source>Prog Mol Biol Transl Sci</source><year>2016</year><volume>144</volume><fpage>487</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">27865465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2016.10.002</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Manna PR, Molehin D, Ahmed AU. Dysregulation of aromatase in breast, endometrial, and ovarian cancers: an overview of therapeutic strategies. Prog Mol Biol Transl Sci. 2016;144:487&#8211;537.<pub-id pub-id-type="pmid">27865465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2016.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stener-Victorin</surname><given-names>E</given-names></name><name name-style="western"><surname>Holm</surname><given-names>G</given-names></name><name name-style="western"><surname>Labrie</surname><given-names>F</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Janson</surname><given-names>PO</given-names></name><name name-style="western"><surname>Ohlsson</surname><given-names>C</given-names></name></person-group><article-title>Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><fpage>810</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20016048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2009-1908</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Stener-Victorin E, Holm G, Labrie F, Nilsson L, Janson PO, Ohlsson C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab. 2010;95:810&#8211;9.<pub-id pub-id-type="pmid">20016048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2009-1908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Ge</surname><given-names>W</given-names></name></person-group><article-title>Steroid hormone profiling in hyperandrogenism and Non-hyperandrogenism women with polycystic ovary syndrome</article-title><source>Reprod Sci</source><year>2022</year><volume>29</volume><fpage>3449</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">35835901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43032-022-00985-0</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ge J, Yang N, Zhang X, Li M, Zhang W, He J, Zhu H, Cheng X, Shen S, Ge W. Steroid hormone profiling in hyperandrogenism and Non-hyperandrogenism women with polycystic ovary syndrome. Reprod Sci. 2022;29:3449&#8211;58.<pub-id pub-id-type="pmid">35835901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43032-022-00985-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gozukara</surname><given-names>I</given-names></name><name name-style="western"><surname>Dokuyucu</surname><given-names>R</given-names></name><name name-style="western"><surname>Ozgur</surname><given-names>T</given-names></name><name name-style="western"><surname>Ozcan</surname><given-names>O</given-names></name><name name-style="western"><surname>Pinar</surname><given-names>N</given-names></name><name name-style="western"><surname>Kurt</surname><given-names>RK</given-names></name><name name-style="western"><surname>Kucur</surname><given-names>SK</given-names></name><name name-style="western"><surname>Dolapcioglu</surname><given-names>K</given-names></name></person-group><article-title>Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model</article-title><source>Gynecol Endocrinol</source><year>2016</year><volume>32</volume><fpage>492</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26772475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09513590.2015.1134478</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Gozukara I, Dokuyucu R, Ozgur T, Ozcan O, Pinar N, Kurt RK, Kucur SK, Dolapcioglu K. Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model. Gynecol Endocrinol. 2016;32:492&#8211;7.<pub-id pub-id-type="pmid">26772475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09513590.2015.1134478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karateke</surname><given-names>A</given-names></name><name name-style="western"><surname>Dokuyucu</surname><given-names>R</given-names></name><name name-style="western"><surname>Dogan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ozgur</surname><given-names>T</given-names></name><name name-style="western"><surname>Tas</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Tutuk</surname><given-names>O</given-names></name><name name-style="western"><surname>Agturk</surname><given-names>G</given-names></name><name name-style="western"><surname>Tumer</surname><given-names>C</given-names></name></person-group><article-title>Investigation of therapeutic effects of erdosteine on polycystic ovary syndrome in a rat model</article-title><source>Med Princ Pract</source><year>2018</year><volume>27</volume><fpage>515</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">30293079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000494300</pub-id><pub-id pub-id-type="pmcid">PMC6422144</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Karateke A, Dokuyucu R, Dogan H, Ozgur T, Tas ZA, Tutuk O, Agturk G, Tumer C. Investigation of therapeutic effects of erdosteine on polycystic ovary syndrome in a rat model. Med Princ Pract. 2018;27:515&#8211;22.<pub-id pub-id-type="pmid">30293079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000494300</pub-id><pub-id pub-id-type="pmcid">PMC6422144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Heidarzadehpilehrood R, Pirhoushiaran M, Abdollahzadeh R, Binti Osman M, Sakinah M, Nordin N, Abdul Hamid H. A review on CYP11A1, CYP17A1, and CYP19A1 polymorphism studies: candidate susceptibility genes for polycystic ovary syndrome (PCOS) and infertility. Genes (Basel) 2022;13:302. <pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes13020302</pub-id><pub-id pub-id-type="pmcid">PMC8871850</pub-id><pub-id pub-id-type="pmid">35205347</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pusalkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Meherji</surname><given-names>P</given-names></name><name name-style="western"><surname>Gokral</surname><given-names>J</given-names></name><name name-style="western"><surname>Chinnaraj</surname><given-names>S</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>A</given-names></name></person-group><article-title>CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>653</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18725155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fertnstert.2008.07.016</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril. 2009;92:653&#8211;9.<pub-id pub-id-type="pmid">18725155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fertnstert.2008.07.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibanez</surname><given-names>L</given-names></name><name name-style="western"><surname>Hall</surname><given-names>JE</given-names></name><name name-style="western"><surname>Potau</surname><given-names>N</given-names></name><name name-style="western"><surname>Carrascosa</surname><given-names>A</given-names></name><name name-style="western"><surname>Prat</surname><given-names>N</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>AE</given-names></name></person-group><article-title>Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing</article-title><source>J Clin Endocrinol Metab</source><year>1996</year><volume>81</volume><fpage>4103</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8923867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.81.11.8923867</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab. 1996;81:4103&#8211;7.<pub-id pub-id-type="pmid">8923867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.81.11.8923867</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>la Marca</surname><given-names>A</given-names></name><name name-style="western"><surname>Morgante</surname><given-names>G</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>M</given-names></name><name name-style="western"><surname>Cianci</surname><given-names>A</given-names></name><name name-style="western"><surname>Petraglia</surname><given-names>F</given-names></name><name name-style="western"><surname>De Leo</surname><given-names>V</given-names></name></person-group><article-title>Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2002</year><volume>78</volume><fpage>1234</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12477517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0015-0282(02)04346-7</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">la Marca A, Morgante G, Palumbo M, Cianci A, Petraglia F, De Leo V. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril. 2002;78:1234&#8211;9.<pub-id pub-id-type="pmid">12477517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0015-0282(02)04346-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suikkari</surname><given-names>AM</given-names></name><name name-style="western"><surname>MacLachlan</surname><given-names>V</given-names></name><name name-style="western"><surname>Montalto</surname><given-names>J</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>I</given-names></name><name name-style="western"><surname>Healy</surname><given-names>DL</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>RI</given-names></name></person-group><article-title>Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment</article-title><source>Hum Reprod</source><year>1995</year><volume>10</volume><fpage>513</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7782424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.humrep.a135980</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Suikkari AM, MacLachlan V, Montalto J, Calderon I, Healy DL, McLachlan RI. Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment. Hum Reprod. 1995;10:513&#8211;9.<pub-id pub-id-type="pmid">7782424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.humrep.a135980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalhori</surname><given-names>Z</given-names></name><name name-style="western"><surname>Azadbakht</surname><given-names>M</given-names></name><name name-style="western"><surname>Soleimani Mehranjani</surname><given-names>M</given-names></name><name name-style="western"><surname>Shariatzadeh</surname><given-names>MA</given-names></name></person-group><article-title>Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome</article-title><source>Cytotherapy</source><year>2018</year><volume>20</volume><fpage>1445</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">30523787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2018.09.005</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kalhori Z, Azadbakht M, Soleimani Mehranjani M, Shariatzadeh MA. Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy. 2018;20:1445&#8211;58.<pub-id pub-id-type="pmid">30523787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2018.09.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Houten</surname><given-names>EL</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>P</given-names></name><name name-style="western"><surname>McLuskey</surname><given-names>A</given-names></name><name name-style="western"><surname>Karels</surname><given-names>B</given-names></name><name name-style="western"><surname>Themmen</surname><given-names>AP</given-names></name><name name-style="western"><surname>Visser</surname><given-names>JA</given-names></name></person-group><article-title>Reproductive and metabolic phenotype of a mouse model of PCOS</article-title><source>Endocrinology</source><year>2012</year><volume>153</volume><fpage>2861</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22334715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2011-1754</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP, Visser JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology. 2012;153:2861&#8211;9.<pub-id pub-id-type="pmid">22334715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2011-1754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldwell</surname><given-names>AS</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>M</given-names></name><name name-style="western"><surname>Desai</surname><given-names>R</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>AC</given-names></name><name name-style="western"><surname>Allan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Handelsman</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Walters</surname><given-names>KA</given-names></name></person-group><article-title>Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models</article-title><source>Endocrinology</source><year>2014</year><volume>155</volume><fpage>3146</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">24877633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2014-1196</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Caldwell AS, Middleton LJ, Jimenez M, Desai R, McMahon AC, Allan CM, Handelsman DJ, Walters KA. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology. 2014;155:3146&#8211;59.<pub-id pub-id-type="pmid">24877633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2014-1196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Lian</surname><given-names>H</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name></person-group><article-title>Integrated single-cell and Spatial transcriptomics reveal microenvironment disruptions by androgen in mouse ovary</article-title><source>iScience</source><year>2024</year><volume>27</volume><fpage>111028</fpage><pub-id pub-id-type="pmid">39429789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2024.111028</pub-id><pub-id pub-id-type="pmcid">PMC11490719</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Luo M, Yang X, Zhou M, Zhang J, Yu B, Lian H, Ye J. Integrated single-cell and Spatial transcriptomics reveal microenvironment disruptions by androgen in mouse ovary. iScience. 2024;27:111028.<pub-id pub-id-type="pmid">39429789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2024.111028</pub-id><pub-id pub-id-type="pmcid">PMC11490719</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>K</given-names></name><name name-style="western"><surname>Fenwick</surname><given-names>M</given-names></name><name name-style="western"><surname>Mora</surname><given-names>J</given-names></name><name name-style="western"><surname>Laird</surname><given-names>M</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>K</given-names></name><name name-style="western"><surname>Franks</surname><given-names>S</given-names></name></person-group><article-title>Onset and heterogeneity of responsiveness to FSH in mouse preantral follicles in culture</article-title><source>Endocrinology</source><year>2017</year><volume>158</volume><fpage>134</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">27819761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2016-1435</pub-id><pub-id pub-id-type="pmcid">PMC5412982</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hardy K, Fenwick M, Mora J, Laird M, Thomson K, Franks S. Onset and heterogeneity of responsiveness to FSH in mouse preantral follicles in culture. Endocrinology. 2017;158:134&#8211;47.<pub-id pub-id-type="pmid">27819761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2016-1435</pub-id><pub-id pub-id-type="pmcid">PMC5412982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SY</given-names></name></person-group><article-title>HDOCK: a web server for protein-protein and protein-DNA/RNA Docking based on a hybrid strategy</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><fpage>W365</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">28521030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx407</pub-id><pub-id pub-id-type="pmcid">PMC5793843</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Yan Y, Zhang D, Zhou P, Li B, Huang SY. HDOCK: a web server for protein-protein and protein-DNA/RNA Docking based on a hybrid strategy. Nucleic Acids Res. 2017;45:W365&#8211;73.<pub-id pub-id-type="pmid">28521030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx407</pub-id><pub-id pub-id-type="pmcid">PMC5793843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sen</surname><given-names>A</given-names></name></person-group><article-title>Androgens regulate ovarian gene expression by balancing Ezh2-Jmjd3 mediated H3K27me3 dynamics</article-title><source>PLoS Genet</source><year>2021</year><volume>17</volume><fpage>e1009483</fpage><pub-id pub-id-type="pmid">33784295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009483</pub-id><pub-id pub-id-type="pmcid">PMC8034747</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Roy S, Huang B, Sinha N, Wang J, Sen A. Androgens regulate ovarian gene expression by balancing Ezh2-Jmjd3 mediated H3K27me3 dynamics. PLoS Genet. 2021;17:e1009483.<pub-id pub-id-type="pmid">33784295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1009483</pub-id><pub-id pub-id-type="pmcid">PMC8034747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parakh</surname><given-names>TN</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>JA</given-names></name><name name-style="western"><surname>Grammer</surname><given-names>JC</given-names></name><name name-style="western"><surname>Weck</surname><given-names>J</given-names></name><name name-style="western"><surname>Hunzicker-Dunn</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeleznik</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Nilson</surname><given-names>JH</given-names></name></person-group><article-title>Follicle-stimulating hormone/camp regulation of aromatase gene expression requires beta-catenin</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>12435</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16895991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0603006103</pub-id><pub-id pub-id-type="pmcid">PMC1533882</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Parakh TN, Hernandez JA, Grammer JC, Weck J, Hunzicker-Dunn M, Zeleznik AJ, Nilson JH. Follicle-stimulating hormone/camp regulation of aromatase gene expression requires beta-catenin. Proc Natl Acad Sci U S A. 2006;103:12435&#8211;40.<pub-id pub-id-type="pmid">16895991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0603006103</pub-id><pub-id pub-id-type="pmcid">PMC1533882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumesic</surname><given-names>DA</given-names></name><name name-style="western"><surname>Winnett</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Grogan</surname><given-names>TR</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>DH</given-names></name><name name-style="western"><surname>Naik</surname><given-names>R</given-names></name><name name-style="western"><surname>Chazenbalk</surname><given-names>GD</given-names></name></person-group><article-title>Randomized clinical trial: effect of low-dose Flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2023</year><volume>119</volume><fpage>116</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">36400597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fertnstert.2022.09.324</pub-id><pub-id pub-id-type="pmcid">PMC12036725</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Dumesic DA, Winnett C, Lu G, Grogan TR, Abbott DH, Naik R, Chazenbalk GD. Randomized clinical trial: effect of low-dose Flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome. Fertil Steril. 2023;119:116&#8211;26.<pub-id pub-id-type="pmid">36400597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fertnstert.2022.09.324</pub-id><pub-id pub-id-type="pmcid">PMC12036725</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>N</given-names></name><name name-style="western"><surname>Chun</surname><given-names>S</given-names></name></person-group><article-title>Association between the serum estrone-to-estradiol ratio and parameters related to glucose metabolism and insulin resistance in women with polycystic ovary syndrome</article-title><source>Clin Exp Reprod Med</source><year>2021</year><volume>48</volume><fpage>374</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">34875745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5653/cerm.2021.04553</pub-id><pub-id pub-id-type="pmcid">PMC8651759</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kim N, Chun S. Association between the serum estrone-to-estradiol ratio and parameters related to glucose metabolism and insulin resistance in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2021;48:374&#8211;9.<pub-id pub-id-type="pmid">34875745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5653/cerm.2021.04553</pub-id><pub-id pub-id-type="pmcid">PMC8651759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Xu XL, Deng SL, Lian ZX, Yu K. Estrogen receptors in polycystic ovary syndrome. Cells 2021;10:459. <pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10020459</pub-id><pub-id pub-id-type="pmcid">PMC7924872</pub-id><pub-id pub-id-type="pmid">33669960</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brawer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>M</given-names></name><name name-style="western"><surname>Farookhi</surname><given-names>R</given-names></name></person-group><article-title>Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat</article-title><source>Biol Reprod</source><year>1986</year><volume>35</volume><fpage>647</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">3098314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod35.3.647</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Brawer JR, Munoz M, Farookhi R. Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. Biol Reprod. 1986;35:647&#8211;55.<pub-id pub-id-type="pmid">3098314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod35.3.647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sotomayor-Zarate</surname><given-names>R</given-names></name><name name-style="western"><surname>Dorfman</surname><given-names>M</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>A</given-names></name><name name-style="western"><surname>Lara</surname><given-names>HE</given-names></name></person-group><article-title>Neonatal exposure to estradiol valerate programs ovarian sympathetic innervation and follicular development in the adult rat</article-title><source>Biol Reprod</source><year>2008</year><volume>78</volume><fpage>673</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18077802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod.107.063974</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sotomayor-Zarate R, Dorfman M, Paredes A, Lara HE. Neonatal exposure to estradiol valerate programs ovarian sympathetic innervation and follicular development in the adult rat. Biol Reprod. 2008;78:673&#8211;80.<pub-id pub-id-type="pmid">18077802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1095/biolreprod.107.063974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>S</given-names></name></person-group><article-title>Relationship between early follicular serum estrone level and other hormonal or ultrasonographic parameters in women with polycystic ovary syndrome</article-title><source>Gynecol Endocrinol</source><year>2020</year><volume>36</volume><fpage>143</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">31242783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09513590.2019.1633296</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Chun S. Relationship between early follicular serum estrone level and other hormonal or ultrasonographic parameters in women with polycystic ovary syndrome. Gynecol Endocrinol. 2020;36:143&#8211;7.<pub-id pub-id-type="pmid">31242783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09513590.2019.1633296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Pan</surname><given-names>B</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name></person-group><article-title>Correlation between steroid levels in follicular fluid and hormone synthesis related substances in its exosomes and embryo quality in patients with polycystic ovary syndrome</article-title><source>Reprod Biol Endocrinol</source><year>2021</year><volume>19</volume><fpage>74</fpage><pub-id pub-id-type="pmid">34001150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12958-021-00749-6</pub-id><pub-id pub-id-type="pmcid">PMC8127216</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Yu L, Liu M, Wang Z, Liu T, Liu S, Wang B, Pan B, Dong X, Guo W. Correlation between steroid levels in follicular fluid and hormone synthesis related substances in its exosomes and embryo quality in patients with polycystic ovary syndrome. Reprod Biol Endocrinol. 2021;19:74.<pub-id pub-id-type="pmid">34001150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12958-021-00749-6</pub-id><pub-id pub-id-type="pmcid">PMC8127216</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome</article-title><source>J Steroid Biochem Mol Biol</source><year>2021</year><volume>206</volume><fpage>105806</fpage><pub-id pub-id-type="pmid">33340681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2020.105806</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yang Z, Zhou W, Zhou C, Zhou Y, Liu X, Ding G, Hu Y, Pan J, Sheng J, Jin L, Huang H. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2021;206:105806.<pub-id pub-id-type="pmid">33340681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2020.105806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>ST</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>PH</given-names></name></person-group><article-title>Function of the granulosa cells in women with polycystic ovary syndrome</article-title><source>Taiwan J Obstet Gynecol</source><year>2024</year><volume>63</volume><fpage>141</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">38485302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjog.2024.01.002</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Yang ST, Chang WH, Wang PH. Function of the granulosa cells in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2024;63:141&#8211;3.<pub-id pub-id-type="pmid">38485302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjog.2024.01.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>XY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HB</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>SG</given-names></name></person-group><article-title>Role of androgen receptor for reconsidering the true polycystic ovarian morphology in PCOS</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>8993</fpage><pub-id pub-id-type="pmid">32488141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-65890-5</pub-id><pub-id pub-id-type="pmcid">PMC7265442</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Gao XY, Liu Y, Lv Y, Huang T, Lu G, Liu HB, Zhao SG. Role of androgen receptor for reconsidering the true polycystic ovarian morphology in PCOS. Sci Rep. 2020;10:8993.<pub-id pub-id-type="pmid">32488141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-65890-5</pub-id><pub-id pub-id-type="pmcid">PMC7265442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lima</surname><given-names>PDA</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DR</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>BK</given-names></name></person-group><article-title>Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>10272</fpage><pub-id pub-id-type="pmid">28860512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-09880-0</pub-id><pub-id pub-id-type="pmcid">PMC5578986</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Lim JJ, Lima PDA, Salehi R, Lee DR, Tsang BK. Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome. Sci Rep. 2017;7:10272.<pub-id pub-id-type="pmid">28860512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-09880-0</pub-id><pub-id pub-id-type="pmcid">PMC5578986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Long</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Z</given-names></name></person-group><article-title>Androgen increases Klotho expression via the androgen receptor-mediated pathway to induce GCs apoptosis</article-title><source>J Ovarian Res</source><year>2023</year><volume>16</volume><fpage>10</fpage><pub-id pub-id-type="pmid">36641458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13048-022-01087-w</pub-id><pub-id pub-id-type="pmcid">PMC9840339</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Zeng X, Zhong Q, Li M, Liu Y, Long S, Xie Y, Mo Z. Androgen increases Klotho expression via the androgen receptor-mediated pathway to induce GCs apoptosis. J Ovarian Res. 2023;16:10.<pub-id pub-id-type="pmid">36641458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13048-022-01087-w</pub-id><pub-id pub-id-type="pmcid">PMC9840339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldwell</surname><given-names>AS</given-names></name><name name-style="western"><surname>Eid</surname><given-names>S</given-names></name><name name-style="western"><surname>Kay</surname><given-names>CR</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>M</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>AC</given-names></name><name name-style="western"><surname>Desai</surname><given-names>R</given-names></name><name name-style="western"><surname>Allan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JT</given-names></name><name name-style="western"><surname>Handelsman</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Walters</surname><given-names>KA</given-names></name></person-group><article-title>Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization</article-title><source>Endocrinology</source><year>2015</year><volume>156</volume><fpage>1441</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">25643156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2014-1887</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Caldwell AS, Eid S, Kay CR, Jimenez M, McMahon AC, Desai R, Allan CM, Smith JT, Handelsman DJ, Walters KA. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization. Endocrinology. 2015;156:1441&#8211;52.<pub-id pub-id-type="pmid">25643156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2014-1887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>M</given-names></name><name name-style="western"><surname>Mizutani</surname><given-names>T</given-names></name><name name-style="western"><surname>Imamichi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Usami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kuribayashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Androgen/androgen receptor pathway regulates expression of the genes for cyclooxygenase-2 and Amphiregulin in periovulatory granulosa cells</article-title><source>Mol Cell Endocrinol</source><year>2013</year><volume>369</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23415714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2013.02.004</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yazawa T, Kawabe S, Kanno M, Mizutani T, Imamichi Y, Ju Y, Matsumura T, Yamazaki Y, Usami Y, Kuribayashi M, et al. Androgen/androgen receptor pathway regulates expression of the genes for cyclooxygenase-2 and Amphiregulin in periovulatory granulosa cells. Mol Cell Endocrinol. 2013;369:42&#8211;51.<pub-id pub-id-type="pmid">23415714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2013.02.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujibe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Baba</surname><given-names>T</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>S</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Mizuuchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Honnma</surname><given-names>H</given-names></name><etal/></person-group><article-title>Androgen potentiates the expression of FSH receptor and supports preantral follicle development in mice</article-title><source>J Ovarian Res</source><year>2019</year><volume>12</volume><fpage>31</fpage><pub-id pub-id-type="pmid">30947734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13048-019-0505-5</pub-id><pub-id pub-id-type="pmcid">PMC6450008</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Fujibe Y, Baba T, Nagao S, Adachi S, Ikeda K, Morishita M, Kuno Y, Suzuki M, Mizuuchi M, Honnma H, et al. Androgen potentiates the expression of FSH receptor and supports preantral follicle development in mice. J Ovarian Res. 2019;12:31.<pub-id pub-id-type="pmid">30947734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13048-019-0505-5</pub-id><pub-id pub-id-type="pmcid">PMC6450008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Sucquart IE, Coyle C, Rodriguez Paris V, Prescott M, Glendining KA, Potapov K, Begg DP, Gilchrist RB, Walters KA, Campbell RE. Investigating GABA Neuron-Specific androgen receptor knockout in two hyperandrogenic models of PCOS. Endocrinology 2024;165:bqae060.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endocr/bqae060</pub-id><pub-id pub-id-type="pmcid">PMC11151696</pub-id><pub-id pub-id-type="pmid">38788194</pub-id></mixed-citation></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scotti</surname><given-names>L</given-names></name><name name-style="western"><surname>Parborell</surname><given-names>F</given-names></name><name name-style="western"><surname>Irusta</surname><given-names>G</given-names></name><name name-style="western"><surname>De Zuniga</surname><given-names>I</given-names></name><name name-style="western"><surname>Bisioli</surname><given-names>C</given-names></name><name name-style="western"><surname>Pettorossi</surname><given-names>H</given-names></name><name name-style="western"><surname>Tesone</surname><given-names>M</given-names></name><name name-style="western"><surname>Abramovich</surname><given-names>D</given-names></name></person-group><article-title>Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients</article-title><source>Mol Reprod Dev</source><year>2014</year><volume>81</volume><fpage>748</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">24889290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.22343</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Scotti L, Parborell F, Irusta G, De Zuniga I, Bisioli C, Pettorossi H, Tesone M, Abramovich D. Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients. Mol Reprod Dev. 2014;81:748&#8211;56.<pub-id pub-id-type="pmid">24889290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrd.22343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanamarlapudi</surname><given-names>V</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>UD</given-names></name><name name-style="western"><surname>Lopez Bernal</surname><given-names>A</given-names></name></person-group><article-title>Luteinizing hormone/chorionic gonadotrophin receptor overexpressed in granulosa cells from polycystic ovary syndrome ovaries is functionally active</article-title><source>Reprod Biomed Online</source><year>2016</year><volume>32</volume><fpage>635</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">27061682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rbmo.2016.03.003</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Kanamarlapudi V, Gordon UD, Lopez Bernal A. Luteinizing hormone/chorionic gonadotrophin receptor overexpressed in granulosa cells from polycystic ovary syndrome ovaries is functionally active. Reprod Biomed Online. 2016;32:635&#8211;41.<pub-id pub-id-type="pmid">27061682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rbmo.2016.03.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catteau-Jonard</surname><given-names>S</given-names></name><name name-style="western"><surname>Jamin</surname><given-names>SP</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>J</given-names></name><name name-style="western"><surname>Dewailly</surname><given-names>D</given-names></name><name name-style="western"><surname>di Clemente</surname><given-names>N</given-names></name></person-group><article-title>Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome</article-title><source>J Clin Endocrinol Metab</source><year>2008</year><volume>93</volume><fpage>4456</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18697861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-1231</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Catteau-Jonard S, Jamin SP, Leclerc A, Gonzales J, Dewailly D, di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:4456&#8211;61.<pub-id pub-id-type="pmid">18697861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-1231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming</surname><given-names>NI</given-names></name><name name-style="western"><surname>Knower</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>KA</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Clyne</surname><given-names>CD</given-names></name></person-group><article-title>Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e14389</fpage><pub-id pub-id-type="pmid">21188138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0014389</pub-id><pub-id pub-id-type="pmcid">PMC3004790</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS ONE. 2010;5:e14389.<pub-id pub-id-type="pmid">21188138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0014389</pub-id><pub-id pub-id-type="pmcid">PMC3004790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>E</given-names></name><name name-style="western"><surname>Shahhoseini</surname><given-names>M</given-names></name><name name-style="western"><surname>Afsharian</surname><given-names>P</given-names></name><name name-style="western"><surname>Karimian</surname><given-names>L</given-names></name><name name-style="western"><surname>Ashrafi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mehraein</surname><given-names>F</given-names></name><name name-style="western"><surname>Afatoonian</surname><given-names>R</given-names></name></person-group><article-title>Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome</article-title><source>Arch Med Sci</source><year>2019</year><volume>15</volume><fpage>887</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">31360184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/aoms.2019.86060</pub-id><pub-id pub-id-type="pmcid">PMC6657255</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hosseini E, Shahhoseini M, Afsharian P, Karimian L, Ashrafi M, Mehraein F, Afatoonian R. Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome. Arch Med Sci. 2019;15:887&#8211;95.<pub-id pub-id-type="pmid">31360184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/aoms.2019.86060</pub-id><pub-id pub-id-type="pmcid">PMC6657255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kaestner</surname><given-names>KH</given-names></name></person-group><article-title>Fox transcription factors: from development to disease</article-title><source>Development</source><year>2016</year><volume>143</volume><fpage>4558</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">27965437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.112672</pub-id><pub-id pub-id-type="pmcid">PMC5201025</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Golson ML, Kaestner KH. Fox transcription factors: from development to disease. Development. 2016;143:4558&#8211;70.<pub-id pub-id-type="pmid">27965437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.112672</pub-id><pub-id pub-id-type="pmcid">PMC5201025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Mirosevich</surname><given-names>J</given-names></name><name name-style="western"><surname>Orgebin-Crist</surname><given-names>MC</given-names></name><name name-style="western"><surname>Matusik</surname><given-names>RJ</given-names></name></person-group><article-title>Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially</article-title><source>Ann N Y Acad Sci</source><year>2005</year><volume>1061</volume><fpage>77</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16467259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1336.009</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, Orgebin-Crist MC, Matusik RJ. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann N Y Acad Sci. 2005;1061:77&#8211;93.<pub-id pub-id-type="pmid">16467259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1336.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Georges A, L&#8217;Hote D, Todeschini AL, Auguste A, Legois B, Zider A, Veitia RA. The transcription factor FOXL2 mobilizes Estrogen signaling to maintain the identity of ovarian granulosa cells. Elife 2014;3:e04207.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.04207</pub-id><pub-id pub-id-type="pmcid">PMC4356143</pub-id><pub-id pub-id-type="pmid">25369636</pub-id></mixed-citation></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Migale</surname><given-names>R</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>M</given-names></name><name name-style="western"><surname>Mitter</surname><given-names>R</given-names></name><name name-style="western"><surname>Rafiee</surname><given-names>MR</given-names></name><name name-style="western"><surname>Wood</surname><given-names>S</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lovell-Badge</surname><given-names>R</given-names></name></person-group><article-title>FOXL2 interaction with different binding partners regulates the dynamics of ovarian development</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><fpage>eadl0788</fpage><pub-id pub-id-type="pmid">38517962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adl0788</pub-id><pub-id pub-id-type="pmcid">PMC10959415</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Migale R, Neumann M, Mitter R, Rafiee MR, Wood S, Olsen J, Lovell-Badge R. FOXL2 interaction with different binding partners regulates the dynamics of ovarian development. Sci Adv. 2024;10:eadl0788.<pub-id pub-id-type="pmid">38517962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adl0788</pub-id><pub-id pub-id-type="pmcid">PMC10959415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>N</given-names></name><name name-style="western"><surname>Fan</surname><given-names>XC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>XX</given-names></name><name name-style="western"><surname>Tyasi</surname><given-names>TL</given-names></name><name name-style="western"><surname>Li</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Wei</surname><given-names>ML</given-names></name><name name-style="western"><surname>Xu</surname><given-names>RF</given-names></name></person-group><article-title>Cooperative effects of FOXL2 with the members of TGF-beta superfamily on FSH receptor mRNA expression and granulosa cell proliferation from Hen prehierarchical follicles</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0141062</fpage><pub-id pub-id-type="pmid">26496659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0141062</pub-id><pub-id pub-id-type="pmcid">PMC4619702</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Qin N, Fan XC, Xu XX, Tyasi TL, Li SJ, Zhang YY, Wei ML, Xu RF. Cooperative effects of FOXL2 with the members of TGF-beta superfamily on FSH receptor mRNA expression and granulosa cell proliferation from Hen prehierarchical follicles. PLoS ONE. 2015;10:e0141062.<pub-id pub-id-type="pmid">26496659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0141062</pub-id><pub-id pub-id-type="pmcid">PMC4619702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>R</given-names></name><name name-style="western"><surname>Melville</surname><given-names>S</given-names></name><name name-style="western"><surname>Violette</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Winer</surname><given-names>S</given-names></name><name name-style="western"><surname>Shoupe</surname><given-names>D</given-names></name><name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>MM</given-names></name></person-group><article-title>A comparison of letrozole regimens for ovulation induction in women with polycystic ovary syndrome</article-title><source>F S Rep</source><year>2024</year><volume>5</volume><fpage>170</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">38983726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xfre.2024.03.004</pub-id><pub-id pub-id-type="pmcid">PMC11228783</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Mandelbaum RS, Agarwal R, Melville S, Violette CJ, Winer S, Shoupe D, Matsuo K, Paulson RJ, Quinn MM. A comparison of letrozole regimens for ovulation induction in women with polycystic ovary syndrome. F S Rep. 2024;5:170&#8211;5.<pub-id pub-id-type="pmid">38983726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xfre.2024.03.004</pub-id><pub-id pub-id-type="pmcid">PMC11228783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>S</given-names></name></person-group><article-title>Current evidence supporting letrozole for ovulation induction</article-title><source>J Hum Reprod Sci</source><year>2013</year><volume>6</volume><fpage>93</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24082649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0974-1208.117166</pub-id><pub-id pub-id-type="pmcid">PMC3778612</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Kar S. Current evidence supporting letrozole for ovulation induction. J Hum Reprod Sci. 2013;6:93&#8211;8.<pub-id pub-id-type="pmid">24082649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0974-1208.117166</pub-id><pub-id pub-id-type="pmcid">PMC3778612</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>